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ABSTRACT 
 
Metabolic Plasticity in the Cellular Stress Response 
by 
Ying Li  
Changes to the metabolism of the cardiomyocyte are driven by complex signaling 
pathways in order to adjust to stress. For instance, HIF-1α is classically known to 
upregulate glycolytic metabolism to compensate for oxygen deficiency. Other important 
effects upon glucose metabolism, which we investigate here more extensively, were 
also observed.  Hearts derived from mice with the cardiac-restricted expression of a 
stabilized form of HIF-1α are remarkably ischemia stress-tolerant. Here, stable isotope-
resolved metabolomic analyses were utilized to investigate glucose cardiometabolism 
remodeling by HIF-1α during ischemia. We found that 13C-lactate accumulation was 
significantly elevated in HIF-1α expressing hearts while paradoxically glycogen was 
maintained to a remarkable extent during an ischemic time course. These findings 
suggested an unexpected source of glucose in HIF-1α hearts during global ischemia. 
Accordingly, the presence of gluconeogenesis in hearts was evaluated.  Indeed, 
gluconeogenic intermediates (i.e. m+3) including glucose-6-phosphate [m+3], fructose-
6-phosphate [m+3], and fructose 1,6-bisphosphate [m+3] were observed at significantly 
elevated levels in the ischemic HIF-1α heart. Collectively, these data establish the 
surprising finding that HIF-1α supports active gluconeogenesis in the heart during 
ischemia.  
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As less is known regarding the effects of CTRP3 we first tested whether CTRP3 
overexpression would protect the ischemic heart. Our data indicate that CTRP3 failed to 
confer ischemic tolerance in heart ex vivo. However, we were able to show that CTRP3 
protected the liver from lipid-induced stress and prevented hepatic lipid accumulation. 
To further investigate the mechanisms of hepatic protective effect mediated by CTRP3, 
we identified the receptor and established that CTRP3 increases oxygen consumption 
in response to lipid overloaded.   
In summary, these data indicate that targeted metabolic rearrangements within 
cardiomyocyte/hepatocyte holds promise for the alleviation of common pathological 
conditions. 
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CHAPTER 1 
 
INTRODUCTION 
Metabolic disturbances have been commonly characterized in diverse diseases 
such as obesity, diabetes, ischemic heart disease, and nonalcoholic fatty liver disease 
(NAFLD) (Ahmed et al. 2012; Ballestri et al. 2016). The mortality rates of heart disease 
and stroke remain the top and third leading causes of death, respectively, in the United 
States over the last four decades (1975-2015).  
During Myocardial infarction blood flow to the heart is stopped whereas during a 
stroke blood flow to the brain is inhibited.  In both cases the resulting hypoxia is a major 
component involved in the severity of these diseases. Thus, identifying the cellular 
response to the low oxygen levels of great clinical importance.   
HIF-1α 
The transcription factor hypoxia inducible factor-1 (HIF-1) functions as a 
principal regulator of the cellular response to hypoxia. HIF-1 is a heterodimeric complex 
comprised of O2-labile α subunit (120 kDa) and the constitutively expressed β subunit 
(91-94 kDa) (Wang and Semenza 1995; Wang et al. 1995). When oxygen is present, 
prolyl hydroxylase (PHDs) hydroxylate at the oxygen-dependent degradation (ODD) 
domain of HIF-1α at proline 402 and proline 564, which targets the protein for rapid 
degradation. Insufficient O2 tension promotes HIF-1α stability by inhibiting the activity of 
PHDs (Salceda and Caro 1997; Huang et al. 1998; Maxwell et al. 1999; Ivan et al. 2001; 
Jaakkola et al. 2001). In addition, during hypoxia, HIF-1α transcription is stimulated.  
Briefly, when oxygen is present factor inhibiting HIF-1 (FIH-1) hydroxylates asparagine 
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803 at the c-terminal transactivation domains (TAD-C) of HIF-1α, which blocks HIF-1α 
from interacting with the coactivators CREB binding protein (CBP) and 300-kilodalton 
coactivator protein (p300) for its transcriptional activity (Mahon et al. 2001; Dames et al. 
2002; Lando, Peet, Gorman, et al. 2002; Lando, Peet, Whelan, et al. 2002; Elkins et al. 
2003; Freedman et al. 2002; Hewitson et al. 2002). However, during hypoxia HIF-1α 
accumulation facilitates the formation of functional heterodimeric transcription factor 
HIF-1 with the coactivators and binds to the core DNA recognition sequence 5′-RCGTG-
3′ within hypoxia response elements (HRE), and activities full transcriptional activity 
(Forsythe et al. 1996; Semenza et al. 1996; Wang et al. 1995). Thus, the stability and 
activity of HIF-1α are closely regulated by oxygen availability. HIF-1α, in turn, initiates 
regulation of a wide variety of downstream target genes that mediate the cellular 
adaptation to hypoxia.  
The role of HIF-1α was first established in erythropoiesis (Semenza and Wang, 
1992; Wang and Semenza, 1996), and later in angiogenesis (Liu et al. 1995; Forsythe 
et al. 1996; Gerber et al. 1997), metabolism (Iyer et al. 1998; Seagroves et al. 2001), 
cell proliferation and apoptosis (Carmeliet et al. 1998). In many pathological settings, 
the HIF-1 signaling pathway is activated in order to cope with hypoxic stress. For 
instance, HIF-1α is essential factor for inflammatory pathogenesis mediated by the 
neutrophils and macrophages (Cramer et al. 2003). It has recently been revealed that 
inflammatory genes are promoted by HIF-1α-mediated metabolic reprogramming by in 
macrophages, dendritic cells (DCs), T-cells, and neutrophils (Corcoran and O’Neill 
2016). HIF-1α is also associated frequently with cancer as a result of intratumoral 
hypoxia and genetic alterations (Semenza 2003). Evidence is observed that HIF-1α is 
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overexpressed in solid tumors (Semenza 2003; Bertout et al. 2008). Stabilized HIF-1α 
has also been described to induce the expression of vascular endothelial growth factor 
(VEGF) in atherosclerotic lesions (Vink et al. 2007).  
HIF-1α has been shown to confer cellular protection in ischemic heart. For 
example, In the setting of ischemic preconditioning (IPC), short-episodes of ischemia 
and reperfusion confer cardioprotection during subsequent prolonged injury of ischemia-
reperfusion (Murry et al. 1986; Rosenberg et al. 2018). The acute cardioprotection was 
lost in HIF-1α heterozygous-null or knockout mice, indicating that HIF-1α activity is 
essential for the potential benefits from IPC stimulus (Cai et al. 2008; Sarkar et al. 
2012). Other downstream targets of HIF-1α such as nitric oxide synthase (NOS), 
vascular endothelial growth factor (VEGF), and heme oxygenase-1 (HO-1), have been 
shown to promote tolerance to ischemic stress in mice hearts or isolated 
cardiomyocytes (Guo et al. 1999; Jung et al. 2000; Ockaili 2005; Li et al. 2007). 
In recent studies, we have utilized a transgenic adult mouse with a cardiac-
specific, oxygen-stabilized, and doxycycline(Dox)-off HIF-1α expression (HIF-1α-PPN) 
to probe the roles of HIF-1α in ischemic tolerance. The results show that HIF-1α elicits 
robust protection in the mouse hearts subjected to the global ischemia, ex vivo (J. Wu et 
al. 2013). These studies also revealed evidence that glucose metabolism was 
remodeled in the HIF-1α hearts (J. Wu et al. 2013). We have previously identified 
several HIF-1α-induced metabolic pathways contributing to the ischemic 
cardioprotection.(J. Wu et al. 2015) In HIF-1α-expressing hearts, the purine nucleotide 
cycle (PNC) was found to be upregulated. The PNC preserves the adenylate energy 
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charge and protects myocardia from toxic accumulation of adenosine during ischemia. 
The nucleotide salvage enzyme hypoxanthine phosphoribosyl transferase (HPRT) was 
also found to be induced by HIF-1α. HPRT recycles the nucleotide degradation product 
hypoxanthine and prevents potential damage from hydrogen peroxide (H2O2) generated 
by xanthine oxidase during reperfusion of ischemic heart (J. Wu et al. 2015). 
CTRP3 
CTRP3 also functions as a metabolic regulator and has versatile effects in 
multi-type tissues (reviewed in chapter 3) (Li et al. 2017). C1q TNF-related protein-3 
(CTRP3) is a distinctive member of highly conserved CTRP family that comprises a 
suite of paralogs of adiponectin (Wong et al. 2004). Several reports have suggested that 
CTRP3 contributes to cardio-metabolic regulation in cardiovascular diseases. For 
example, myocardial infarction (MI) was shown to lead to lower CTRP3 tissue 
expressions and plasma CTRP3 level (Yi et al. 2012; D. Wu et al. 2015). Infusions of 
globular CTRP3 or CTRP3 adenovirus improved functional recovery of the left ventricle 
and prevented pathological remodeling of fibrosis following MI injury in myocardia (Yi et 
al. 2012; D. Wu et al. 2015). The anti-fibrotic effect of CTRP3 was induced by inhibitions 
of phosphorylation of Smad-3 in post-infarct myocardia (D. Wu et al. 2015). The vessels 
formation in the infarcted border zone has been shown to be promoted through CTRP3-
induced phosphorylations of Akt, HIF-1α, and VEGF in the myocardium (Yi et al. 2012). 
Finally recent studies showed that the treatment of CTRP3 ameliorates mitochondrial 
dysfunction after hypoxia-reoxygenation injury in neonatal cardiomyocytes (Zhang et al. 
2017).  
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Taken together, these data suggested the potential of CTRP3 as a prospective 
modulator for ischemic heart disease. We therefore sought to probe the role of CTRP3 
in cardioprotection. A transgenic mouse model of CTRP3 overexpression was used in 
this study. WT and CTRP3 overexpressing hearts were retrograde perfused via the 
aorta and subjected to 30 mins of ischemia followed by 30 mins of reperfusion, ex vivo. 
Subsequent recovery of function and tissue viability were assessed upon reperfusion of 
heart. Our results showed that recovery of left ventricular developed pressure (LVDP) in 
CTRP3 overexpressing hearts after ischemia, was not significantly better (22% vs 39%, 
P>0.05). (Figure 1.1) In addition, there are no significant differences in tissue viability 
after reperfusion between WT and CTRP3 overexpressing hearts. (Figure 1.2) These 
results indicated that CTRP3 does not confer specific cardioprotection at least in this 
model of hypoxic injury.  
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Figure 1.1: Cardiac Response to Ischemic Stress. A. condensed pressure tracings were shown 
from Langendorff-perfused hearts derived from wildtype (WT) and CTRP3 overexpressing 
(CTRP3) mice. Following 20 mins of pre-ischemic perfusion, hearts were subjected to 30 mins 
of ischemia and subsequently to 30 mins of reperfusion and left ventricular developed pressure 
(LVDP) was measured. B. quantification of the recovery of LVDP after ischemia, expressed as a 
percent of pre-ischemic LVDP is shown. P > 0.05 vs. WT; n = 3-5 hearts. 
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Figure 1.2: Myocardial Ischemic Injury Indicated by Triphenyltetrazolium Chloride (TTC) 
Staining. A. Langendorff-perfused hearts derived from wildtype (WT) and CTRP3 
overexpressing (CTRP3) mice were collected following 30 mins of reperfusion after 30 mins of 
ischemia. Viable (red) and inviable tissue (pale) were shown in sectioned hearts. B. 
quantification of viable tissue, expressed as a percent of each heart tissue. P > 0.05 vs. WT; n = 
3-5 hearts. 
By comparison, CTRP3 appears to protect the liver from lipid-induced stress 
and regulate hepatic metabolism. For example, we initially established evidence that 
CTRP3 maintains glucose homeostasis by suppression of hepatic gluconeogenesis via 
protein kinase B (Peterson et al. 2010). Insulin resistance and dyslipidemia have 
emerged as the most predominant features and pathological basis of NAFLD. NAFLD 
refers to a spectrum of pathological phenotypes comprising simple steatosis, 
nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. Accumulation of 
hepatocellular lipid metabolites is recognized as the first “hit” of complex mechanisms of 
NAFLD to induce the ultimate liver injury (Perla et al. 2017). The net lipid flux is 
enhanced and causes dysregulation of lipid and lipoprotein metabolism, eventually 
developing into the overload of lipid in hepatocytes. The excessive lipid retention leads 
to insulin resistance via the stimulation of glucose secretion and inhibition of the 
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phosphorylation of the insulin receptor substrate (IRS)-1/ IRS-2 in liver (Perla et al. 
2017).  
Interestingly, we have found that CTRP3 overexpressing efficiently limits the 
development of high fat diet-induced hepatic steatosis and insulin resistance 48. This 
effect is associated with the suppression of hepatic triglyceride synthesis enzymes 
(Peterson et al. 2013). Consistent with in vivo data, rCTRP3 treatment reduced fatty 
acid synthesis and lipid accumulation in rat H4IIE hepatocytes (Peterson et al. 2013). In 
CTRP3 knockout mice, however, hepatic triglycerides were elevated after high fat diet 
fed.(Wolf et al. 2016) In contrast, these CTRP3-induced metabolic changes have not 
been found in mice fed with a low fat diet (Peterson et al. 2013; Wolf et al. 2016). 
Collectively, although these data indicate that CTRP3 regulate hepatic lipid metabolism 
in response to high fat diet-induced stress, the mechanisms deserve to be further 
investigated. Thus it needs to be clarified whether CTRP3 acts directly or is mediated by 
potential receptors in hepatocytes.  
Overall Hypothesis and Specific Aims 
The overall goal of this dissertation was to investigate mechanisms to 
manipulate the cellular response to stress to prevent/treat disease. Based on the 
discussion above, this study aimed to identify unique metabolic mechanisms induced by 
HIF-1α and CTRP3 that respond to stress conditions. Aim 1) was to determine the 
cardiometabolic flux, particularly as it relates to glucose metabolism and to further 
elucidate the mechanisms responsible for HIF-1α’s ischemic protection. In chapter 2 we 
describe how we used metabolomics analysis to show that glucose metabolism was 
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different in the HIF-1α-expressing heart during ischemia. Specifically, we observed 
convincing evidence that HIF-1α induces gluconeogenic pathway. These studies have 
identified a number of potential mechanisms to explain the cardioprotective effects of 
HIF-1α. Aim 2) was to investigate the heart and hepatic protective effects of CTRP3 
based upon remodeling of lipid metabolism to high fat diet-induced stress. In chapter 3 
we review CTRP3 function and regulation. In chapter 4 we demonstrate that CTRP3 
promotes fatty acid utilization following lipid overload in vitro and identified a putative 
receptor for CTRP3. 
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CHAPTER 2 
 
HIF-1α IN HEART: EVIDENCE OF GLUCONEOGENESIS IN MYOCARDIUM 
DURING ISCHEMIA 
 
Li Y 1, Warmoes MO 2, Lin PH 2, Peterson JM 1,3, Bolton NW 1 and Wright GL 1. 
 
1 Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State 
University, Johnson City, TN 2 Center for Environmental and Systems Biochemistry, Markey 
Cancer Center, University of Kentucky, Lexington, KY  
3 Department of Health Sciences, College of Public Health, East Tennessee State University, 
Johnson City, TN 
 
ABSTRACT 
Hypoxia inducible-1α (HIF-1α) is a transcription factor that directs multiple cellular 
changes to adapt to low oxygen conditions. Previously we have shown that hearts derived 
from mice with the cardiac-restricted overexpression of HIF-1α are remarkably ischemia 
stress-tolerant (4). The current studies are designed to further probe the metabolic 
rearrangements directed by HIF-1α, particularly as they relate to glucose metabolism. U-
13C6 glucose was loaded into Wild-type (WT) and HIF-1α expressing hearts for 30 mins, 
ex vivo. Subsequently the hearts were subjected to global zero-flow ischemia (0, 5, 10, 
15, and 30 mins) and flash frozen. Polar metabolites were subsequently extracted. In 
parallel, myocardial protein was collected for western blot analysis. The incorporation of 
13C in the metabolome reservoir of the heart was determined by Nuclear Magnetic 
Resonance (NMR) spectroscopy and Ion-Cyclotron Resonance coupled Mass 
Spectrometry (ICR-MS). Indicating enhanced glycolytic flux, 13C-lactate accumulated in 
HIF-1α hearts and WT hearts as ischemia progressed but was significantly elevated in 
the HIF-1α hearts. Glucose reserves (i.e. glycogen) are maintained to a remarkable extent 
at 5, 10 and 30 mins of ischemia in HIF-1α hearts while, in stark contrast, glycogen is 
largely depleted after 5 mins of ischemia in WT hearts. 13C-Glucose incorporation into 
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glycogen is maintained at pre-ischemic levels in HIF-1α hearts for up to 30 mins of 
ischemia while becoming undetectable in WT hearts. These findings suggested an 
unexpected source of glucose in the ischemic HIF-1α heart.  Accordingly, the presence 
of gluconeogenesis in hearts was evaluated.  Indeed, IC-MS detected gluconeogenic 
intermediates (i.e. m+3) including glucose-6-phosphate [m+3], fructose-6-phosphate 
[m+3], and fructose-1-6-bisphosphate [m+3] at statistically elevated levels in HIF-1α 
hearts during ischemia. Taken together, these data establish the surprising finding that 
HIF-1α supports active gluconeogenesis in the heart during ischemia.  
INTRODUCTION 
Hypoxia inducible factor-1α (HIF-1α) is “master regulatory” transcription factor 
that governs the expression of over 120 genes, including those functioning metabolic 
adaptation, angiogenesis, tumorigenesis, inflammation, and apoptosis (1). HIF-1α is 
functional as a heterodimer composed of the oxygen-regulated α-subunit and a 
constitutively expressed β-subunit (also known as ARNT). The heterodimers bind to 
hypoxia response elements (HREs) to regulate nuclear transcriptional activity of target 
genes.   
The stability of HIF-1α is regulated by the proline hydroxylase domain-containing 
proteins (PHD) which serve as oxygen sensors. HIF-1α is subjected to hydroxylation 
which leads to its ubiquitination by the von Hipple-Lindau protein (pVHL) for consequent 
proteasomal degradation (2). The activity of the dioxygenase PHDs diminishes with 
oxygen shortage and the reduced post-translation hydroxylation of HIF-1α results in its 
stabilization. Hypoxia also lowers the activity of the factor inhibiting HIF (FIH), an 
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asparaginyl hydroxylase which inhibits HIF-1α transcriptional activity by preventing 
recruitment of co-activator (3). In these studies, we use a transgenic mouse model 
containing HIF-1α cDNA with alanine substitutions at Pro402, Pro564, and Asn803 as 
described in our previous studies (4, 5). This HIF-1α construct displays full transcriptional 
activity and the protein is stabilized under normoxic conditions. Moreover, HIF-1α protein 
(termed as “HIF-1α-PPN) is yoked to a TET-off γ-myosin promoter effecting 
cardiomyocyte-specific expression controlled by a doxycycline-diet. 
Hypoxia is fundamental stimuli that initiates a number of cellular adaptive 
responses in the myocyte. In heart, it has been widely known that flux through glycolysis 
is stimulated and lactate production is preferred while fatty acid oxidation is actively 
suppressed during low oxygen availability. Glucose transportation is also increased by 
HIF-1α through an upregulation of GLUT-1 (6). During chronic hypoxia, reduced 
mitochondrial metabolism is a strategy to maintain redox homeostasis and cell survival 
against excessive levels of reactive oxygen species (ROS). For example, pyruvate 
dehydrogenase kinase 1 (PDK1) prevents the conversion from pyruvate to acetyl-CoA 
through the tricarboxylic acid (TCA) cycle, which allows the shift from oxidative to 
glycolytic metabolism.  The gene encoding PDK1 protein is directly activated by HIF-1α, 
thus shifting glucose from the oxidative to the fermentative pathways (7, 8).   
In a transgenic murine model where HIF-1α is stably expressed in heart, we 
previously demonstrated remarkable protection against ischemia-reperfusion injury, ex 
vivo, and anaerobic fumarate respiration which preserves mitochondrial polarization 
during anoxia (4). Further investigation revealed that AMP deaminase (AMPD), the entry 
  21 
point of the purine nucleotide cycle (PNC), is upregulated by HIF-1α, which results in 
inhibiting production of adenosine in myocardium during ischemia and favors production 
of fumarate to support the above mentioned fumarate reductase activity (5). These results 
indicated that HIF-1α regulates nucleotide metabolism as a compensatory response to 
metabolic perturbations which provides fumarate and conserves the nucleotide pool 
during hypoxia (5). Despite these recent advances in understanding the mechanisms of 
cardioprotection induced by HIF-1α during ischemic stress, the role of remodeling of 
glucose metabolism by HIF-1α remains unclear. These studies were undertaken to further 
probe the cardio-specific role of HIF-1α in cardioprotection, especially as they are related 
to glucose metabolism. 
Metabolomics is a platform enabling the simultaneous qualitative measurement 
of metabolites in biological samples. 1H NMR and MS techniques are two popular 
analytical techniques applied to the analysis of the metabolic profile (9, 10). Here, a 
metabolomics approach based on 1H NMR and MS was used to quantify metabolite levels 
in heart during ischemia and to probe the underlying metabolic mechanisms of 
cardioprotection elicited by HIF-1α. Studies were performed in perfused mouse hearts 
that had undergone ischemia following the incorporation of Uniform-13C6-(U-13C6) glucose, 
with subsequent determination of metabolites downstream in glucose metabolism. 
EXPERIMENTAL PROCEDURES 
Animals. Male B6C3F1 mice contain a doxycycline-restraining HIF-1α transgene 
(HIF-1α-PPN) that has been described previously (4). These HIF-1α-PPN mice are fed 
daily with a doxycycline-loaded diet (625 mg/kg, Harlan Research Laboratories, Madison, 
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WI). HIF-1α specific stably expressing in mouse heart is elicited after 5-7 days following 
switching to regular diet. All wildtype and HIF-1α-expressing mice were used for the study 
at 3.5-4.5 months of age. Procedures on animal experiments were performed in 
accordance with the regulations issued by the East Tennessee State University 
Committee on Animal Care. 
Langendorff perfusion. Hearts were retrograde perfused through the aorta using 
methods described previously. 4 Krebs-Henseleit buffer containing (mM): 118.5 NaCl, 4.7 
KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 NaCHO3, 2.5 CaCl2, and 10.6 glucose (U-13C6-glucose, 
Cambridge Isotope Laboratories, Inc. Andover, MA) that has been made and then 
warmed at 37°C using refrigerated circulating bath (VWR, Radnor, PA) during perfusion. 
The buffer was equilibrated with mix of 95% O2/5% CO2 for at least 20 mins.  U-13C6-
glucose was infused of 30 mins. Then hearts are subjected to global ischemia for 0, 5, 
10, 15 or 30 mins, respectively. Hearts were flash-frozen by clamping with a set of 
Wollenberger tongs that were prechilling in liquid nitrogen, where upon the hearts were 
ground into a fine powder using a mortar and pestle with liquid N2.  
Preparation of sample. The frozen powdered heart samples were quenched in a 
cold cocktail of CH3CN:ddH2O=2:1.5 (CH3CN: Sigma, St. Louis, MO) after which, polar 
compounds were extracted according to the lab protocols from Resource Center for 
Stable Isotope-Resolved Metabolomics (University of Kentucky, KY). Briefly, 1mL of 
CHCl3 (Sigma, St. Louis, MO) was added to ensure the ratio in samples (CH3CN:ddH2O: 
CHCl3=2:1.5:1), shaken vigorously and vortexed, then centrifuged at 3,500 g at 4°C for 
20 mins. The polar fraction (upper layer) and protein (middle layer) were collected and 
  23 
lyophilized for further experiments. Levels of metabolites in hearts were determined by 
NMR and ICR/MS Spectrometers (Resource Center for Stable Isotope-Resolved 
Metabolomics, University of Kentucky, KY).  
1D 1H and 1H{13C} HSQC NMR analyses. Polar extracts were reconstituted in 
D2O (> 99.9%, Cambridge Isotope Laboratories, MA) containing 0.1 mM EDTA 
(Ethylenediaminetetraacetic acid, Sigma Aldrich, St. Louis, MO) and 0.5 mM d6-2,2-
dimethyl-2-silapentane-5-sulfonate (DSS) (Cambridge Isotope Laboratories, Tewksbury, 
MA) as internal standard were performed on a DD2 14.1 Tesla NMR spectrometer 
(Agilent Technologies, CA) equipped with a 3 mm inverse triple resonance HCN 
cryoprobe. 1D 1H spectra were acquired with standard PRESAT pulse sequence at 15°C. 
A total of 16384 data points were acquired with 2 s acquisition time, 512 transients, 12 
ppm spectral width, and 4 s recycle delay time during which water peak was irradiated by 
soft pulse for suppression. The spectra were then linear predicted and zero filled to 128k 
points and apodized with 1 Hz exponential line broadening. 1D HSQC spectra were 
recorded with 13C adiabatic decoupling scheme for broad range decoupling during proton 
acquisition time of 0.25 s. 1796 data points were collected each transient and a total of 
1024 transients were acquired with 12 ppm spectral width. The HSQC spectra were zero 
filling to 16k data points before Fourier transformation and then apodized with unshifted 
Gaussian function and 4 Hz exponential line broadening. Metabolites were assigned by 
comparison with in-house (11) and public NMR databases. Metabolite and their 13C 
isotopomers were quantified using the MestReNova software (Mestrelab, Spain) by peak 
deconvolution. The peak intensities of metabolites obtained were converted into nmoles 
by calibration against the peak intensity of internal standard DSS (27.5 nmoles) at 0 ppm 
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for 1H spectra and that of Lac-3 at 1.32 ppm (nmoles determined from 1D 1H spectra) for 
HSQC spectra before normalization to the dry residue weight of each sample extracted. 
Ion Chromatography-Mass Spectrometry (IC-MS) analyses. Unless stated 
otherwise, ICMS analysis was performed as previously described (12, 13). In short, polar 
extracts were reconstituted in 20 µL nanopure water of which 10 µL was injected for 
analysis on a Dionex ICS-5000+ion chromatograph interfaced to an Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). MS1 mass 
spectra were acquired at a resolution setting of 500,000 (FWHM at m/z 200) and an m/z 
range from 80 to 700. The chromatograph was outfitted with a Dionex IonPac AG11-HC-
4 µm guard and column (both 2 × 50 mm). MS1 peak areas for isotopologues were 
integrated and exported to Excel via the Thermo TraceFinder (version 3.3) software 
package. Peak areas were corrected for natural abundance as previously described (14). 
Western Blotting. Protein samples were separated in Pierce Tris-HEPES-SDS 
4–20% precast polyacrylamide gels (Thermo scientific).  Proteins were transferred to 
polyvinylidene difluoride membranes (BioRad, Richmond, CA) at 300 mA for 1.5 hours.  
following transfer, Ponceau S (Sigma) staining was used to ensure complete transfer 
and equal protein loading.  Membranes were blocked in 5% nonfat dry milk in 1xTBS 
with 0.1% Tween 20 (TBS-T) for 1 hour at room temperature. Phospho-glycogen 
synthase (Ser641) expression was probed with a rabbit monoclonal primary antibody 
(Cell signaling #3891) at 1:1,000 dilution in TBS-T. The membrane was incubated at 
4°C overnight and washed for 10 mins x 3 times in TBS-T before incubation with goat 
anti-rabbit horseradish peroxidase-conjugated (HRP) secondary antibody.  Protein 
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bands were detected using the Pierce supersignal chemiluminescence substrate 
(Thermo scientific) in the G:Box fluorescence and chemiluminescence imaging system 
(Syngene, Frederick, MD).  Densitometry was performed using ImageJ (National 
Institutes of Health, Bethesda, MD).  
Statistical Analysis. Quantified metabolite levels (umol or nmol/g protein) from 
each experiment were expressed as means±SEM. Independent replicates were 
combined and analyzed with a two-way ANOVA followed by Bonferroni's (for 
metabolomics data) or Sidak’s (for western blot data) multiple comparisons analysis. 
Statistical analyses were performed in Graphpad Prism 6 (La Jolla, CA). 
RESULTS 
Enhanced glycolytic flux in HIF-1α-expressing heart in response to ischemia with 
the unexpected failure to deplete glycogen levels. 
 
HIF-1α expression was specifically induced in murine cardiomyocytes through 
the removal of Doxy diet for 5-7 days prior to the experiment. Wild-type (WT) and HIF-1α 
expressing hearts were perfused with 10.6 mM U-13C6 glucose for 30 mins, ex vivo in the 
loading phase. Subsequently the hearts were subjected to global ischemia (for 0, 5, 10, 
15 and 30 mins), flash frozen and metabolites were extracted following established 
procedures. Extracted metabolites were quantitated in spectra of 1H heteronuclear single 
quantum coherence (HSQC) and 1H spectra with presaturation (PRESAT), respectively. 
All quantitation is normalized to the dry residue protein weight (umol/g). In HSQC spectra, 
metabolites assessed are linked to 13C directly, whereas it is linked to total amount of 
molecule in PRESAT spectra.  
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We found that in HSQC spectra, 13C-labeled lactate production increased in both 
of WT and Doxy-off-induced HIF-1α hearts during ischemia (Figure 2.1B). However, the 
upward trend is interrupted in WT hearts at 15 mins, while 13C-labeled lactate production 
continues and is significantly elevated in HIF-1α hearts at 30 mins of ischemia. This is 
consistent with the increased glycolytic flux that we and others, have previously noted 
accompanies HIF-1α expression (4, 22). Given that we are examining isolated hearts 
undergoing global ischemia, glycogen is the only acknowledged source of available 
glucose reserves. Accordingly, 13C-labeled glycogen levels in WT and HIF-1α hearts were 
assessed at indicated ischemic times in HSQC spectra (Figure 2.1A).  As expected 
glycogen glucose reserves are depleted rapidly in WT hearts during ischemia. In stark 
contrast, HIF-1α hearts maintained glycogen levels at pre-ischemic levels after 30 mins 
of ischemia. These striking results were followed by the assessment of PRESAT spectra 
glycogen levels (Figure 2.1C), which measures the total amount of glycogen (12C and 13C-
labeled glycogen). 13C-labeled glycogen levels of satellite B in PRESAT spectra were 
measured as well (Figure 2.1E). Similar to the HSQC spectra, 13C-labeled glycogen levels 
are maintained to a remarkable extent in HIF-1α hearts during ischemia. Indicating 
enhanced glycolytic flux, 13C-lactate production was elevated in the HIF-1α as compared 
to WT hearts, especially after 15 mins of ischemia where lactate levels continued to rise 
in the HIF-1α hearts while peaking within 5-10 mins of ischemia in WT hearts (Figure 2.1B, 
D, and F). In addition, lactate levels were confirmed to be significantly elevated in 13C-
labeled satellite A and satellite B in HIF-1α hearts at 30 mins of ischemia, compared to 
WT (Figure 2.1D and F).  
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Figure 2.1: Glycogen Reserves Maintained despite Increased Lactic Acid Production by HIF-1α-
expressing Hearts for up to 30 mins of Ischemia. Langerdorff perfused hearts were loaded with 
U-13C6 glucose for 30 mins and then subjected to the indicated times for ischemia. 13C-labeled 
metabolites derived from WT and HIF-1α mouse hearts were quantitated in 1H heteronuclear 
single quantum coherence (HSQC) spectra by NMR spectroscopy (Figure 1, A, B). Assessment 
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of (A) glycogen levels and (B) lactic acid production in heart tissues at corresponding ischemic 
times. The glycogen levels are expressed as the percentage of change relative to pre-ischemic 
value. 
 
12C- and 13C-labeled metabolites are able to be determined synchronously in 1H spectra with 
presaturation (PRESAT) by NMR spectroscopy (Figure 1, C-F). (C) 12C-labeled glycogen levels, 
(E) 13C-labeled glycogen levels, and (D, F) 13C-labeled lactic acid production in WT and HIF-1α-
PPN/tTA mouse hearts are shown at indicated ischemic times. All glycogen levels are expressed 
as the percentage change relative to pre-ischemic value. * P<0.05 vs WT at corresponding 
ischemic times; n= 3-5 hearts. 
Active gluconeogenesis is responsible for the maintenance of glycogen levels and 
glucose:glycogen turnover at later times of ischemia in the HIF-1α-expressing 
heart. 
We next investigated 13C-labeled isotopologues of metabolites using IC-MS. 
13C-labeled metabolites of glucose are shown (Figure 2.3). During ischemia, glycolysis 
of 13C-labeled glucose increases as a compensatory ATP source in hearts during 
ischemia, explaining the elevated lactate production in HIF-1α hearts, compared with 
WT. The maintenance of glycogen levels suggested an unexpected source of glucose is 
present in what is an essentially closed perfusion system. Accordingly, we investigated 
the presence of gluconeogenesis intermedates. That is, metabolites labeled with three 
carbons (13C-[m+3]), such as Fructose 1,6-bisphosphate, Fructose 6-phosphate, 
Glucose 6-phosphate, and Glucose 1-phosphate, are considered as 13C-labeled 
glyconeogenic intermediates (Figure 2.3). We found that Glucose 6-phosphate [m+3] 
and Fructose 6-phosphate [m+3] increased significantly in HIF-1α hearts at 30 mins of 
ischemia, compared with WT hearts.  We also observed that Fructose 1,6-bisphosphate 
[m+3] was elevated significantly in HIF-1α hearts at 15 mins of ischemia, compared with 
WT (Figure 2.2).  
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Figure 2.2: Elevated 13C-labeled Gluconeogenetic Intermediates [m+3] in HIF-1α Ischemic Hearts. 
13C-labeled gluconeogenetic intermediates are determined using IC-MS. (A) glucose-6- 
phosphate, m+3 (G6P). (B) fructose-6-phosphate, m+3 (F6P). (C) fructose 1-6-bisphosphate, 
m+3 (F 1,6-BP). * P<0.05 vs WT at corresponding ischemic period; n= 3-5 hearts.  
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Figure 2.3: Schematic viewing of U-13C-glucose metabolism in heart. Black dots indicate 13C-
atoms and grey dots indicate 12C-atoms. In cytosol, U-13C-labeled glucose is phosphorylated and 
converted to [m+6] 13C-labeled G6P, F6P, F1,6-BP, then split up to [m+3] 13C-labeled DHAP (not 
shown) and GAP. Eventually, [m+3] 13C-atom will be passed into PEP and pyruvate that can be 
converted into [m+3] 13C-labeled lactate and alanine under anaerobic condition. Pyruvate is 
actively transported into the mitochondria, thereafter in the matrix, there are 2 different routes. 1. 
pyruvate could be converted into [m+2] 13C-labeled acetyl-CoA by the PDH complex. acetyl-CoA 
brings the acetyl group into the TCA cycle and then produce ATP by the oxidative phosphorylation 
under the aerobic conditions, acetyl-CoA is also precursors for de novo biosynthesis of fatty acids 
and cholesterol, [m+2] and [m+4] OAA will be produced by this way (not shown). 2. pyruvate could 
be converted directly by PC to [m+3] 13C-labeled OAA. Since OAA is limited to across inner 
membrane of the mitochondria, so it needs to be transported by the malate-aspartate shuttle into 
the cytosol, there, PEPCK de-carboxylates and phosphorylates OAA for its conversion to [m+2] 
(not shown) and [m+3] 13C-labeled PEP. Then 1-molecular [m+3] 13C-labeled GAP combines with 
1-molecular endogenous 12C-labeled GAP to generate [m+3] 13C-labeled F1,6-BP, F6P, G6P, and 
glucose through the gluconeogenesis. This glucose production could contribute to the increased 
glycogen level by glycogenesis in HIF-1α heart. (GULT: Glucose transporter, G6P: glucose 6-
phosphate, F6P: Fructose 6-phosphate, F1,6-BP: Fructose 1,6-bisphosphate, DHAP: 
Dihydroxyacetone phosphate, GAP: Glyceraldehyde 3-phosphate, PEP: Phosphoenolpyruvate, 
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PDH: Pyruvate dehydrogenase, HK: Hexokinase, PFK: phosphofructokinase, PK: pyruvate 
kinase, LDH: Lactate Dehydrogenase, TCA cycle: tricarboxylic acid cycle, OAA: oxaloacetate, PC: 
pyruvate carboxylase, PEPCK: phosphoenolpyruvate carboxykinase, FBP: fructose 1,6-
bisphosphatase, G6PC: glucose 6-phosphatase.) 
HIF-1α-expressing hearts more effectively mobilize glycogen synthesis during 
Ischemia. 
 
The continued incorporation of 13C-glucose into glycogen even at late times of 
ischemia coupled to the continued accumulation of lactate suggests that the HIF-1α 
hearts were more effective at mobilizing glucose from glycogen. Accordingly, the status 
of glycogen synthase (GS) phosphorylation was examined. P-GS is inactivated and 
favors glucose mobilization (Figure 2.4). We observed that in hearts, the phosphor-
glycogen synthase is dynamically regulated by ischemia and significantly induced by 
HIF-1α. 
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Figure 2.4: Enhanced glycolytic flux in HIF-1α-expressing heart during ischemia. Tissue samples 
from WT and HIF-1α mice hearts were collected following various ischemic periods (0, 5, 10, 15, 
and 30 mins) for Western Blotting analysis. (A) the protein expression of phosphor-glycogen 
synthase (pGS) as determined for these indicated heart groups. (B) quantification of band 
intensity was performed in imageJ. * P<0.05 vs WT at corresponding ischemic period; n= 4. 
DISCUSSION 
A considerable amount of research has demonstrated the protective effect of HIF-
1α against ischemia in heart (4, 15, 16). During chronic myocardial ischemia, 
downregulation of fatty acids and ketone body oxidation is accompanied by upregulation 
of substrate preference toward glucose utilization (17). Hence it is of acute interest to 
understand the role of glucose metabolism in myocardial tolerance to hypoxic stress. It is 
well established that HIF-1α increases the glycolytic capacity by positively targeting 
glycolytic enzyme expression.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
Hexokinase 1/2 (HK1/2) and Triosephosphate isomerase (TPI) under anaerobic, or 
aerobic conditions (18, 19, 20).  In these studies, we find that that lactate production is 
enhanced in HIF-1α hearts, and that 13C incorporation of lactate continues for up to 30 
mins of ischemia. This is consistent with our previous data where we showed that lactate 
production in 6D-induced HIF-1α-PPN mouse hearts following ischemia is significantly 
elevated (4). Taken together the findings indicate that HIF-1α hearts are more effective 
at maintaining glycolytic activity during total global heart ischemia.  We will discuss the 
reasons for this below.    
Our previous work has demonstrated that the purine nucleotide cycle (PNC), a 
AMP salvage pathway is upregulated by HIF-1α.  The PNC generates fumarate from 
aspartate during instances where AMP levels rise, such as strenuous exercise or 
ischemia (31). We have also shown that the PHD-pathway/HIF-1α confers upon myocytes 
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the ability to perform anaerobic mitochondrial respiration using fumarate as an electron 
acceptor. In this scenario mitochondrial complex II reduces fumarate to succinate.  This 
allows for continued electron flux through complex I when oxygen is absent. These 
mechanisms probably result in two major consequences that impact glycolysis.  Firstly, 
during ischemia, NAD+ continues to be regenerated, thus allowing glycolysis to proceed 
unimpeded.   We believe that this accounts, in part, for the findings that lactate continues 
to accumulate and incorporate 13C label even after 30 mins of global ischemia in the HIF-
1α hearts.   Secondly, AMP deaminase, the rate-limiting enzyme of the PNC that is 
upregulated by HIF-1α has been posited to positively regulate phosphofructokinase (31).  
Ammonium ions produced by AMP deaminase activate phosphofructokinase, which in 
turn, stimulates glycolysis. Clearly, HIF-1α exerts its effects through multiple regulatory 
mechanisms to many metabolic pathways in order to situate the myocyte to tolerate a low 
oxygen/substrate environment.  
The most remarkable finding of this study is the extent to which 13C-labeled and 
total glycogen levels were maintained in HIF-1α hearts at ischemic times of up to 30 mins. 
This surprising finding suggested an unexpected source of glucose in the un-perfused 
ischemic HIF-1α heart. Accordingly, we investigated the levels of gluconeogenic 
intermediates (i.e. [M+3] isotopologues of glycolytic intermediates; consult figure 2.2 and 
2.3) in the HIF-1α hearts.  Indeed, we find that the levels of gluconeogenic intermediate 
metabolites are highly elevated in the HIF-1α hearts during ischemia as compared to the 
WT hearts.  Taken together these findings indicate that active gluconeogenesis accounts 
for the failure to deplete glycogen and glucose and fructose phosphate species in the 
HIF-1α hearts.   
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Two ATP equivalents are produced in anaerobic glycolysis.  In contrast, 4 ATP 
and 2 GTP are consumed to produce glucose via gluconeogenesis.  The HIF-1α heart 
does have sources of anaerobically produced high energy phosphates, including the 
aforementioned “fumarate respiration”, that are not available to the naïve WT hearts.  
Nonetheless, the question arises, what advantage might arise to expending scarce ATP 
to maintain glucose/glycogen levels and glycolytic activity.   We believe the answer may 
lie in the nature of glycolytic ATP utilization versus oxidatively produced ATP. Unlike 
myocardial contractile function, which is supported primarily by energy derived oxidative 
phosphorylation, sarcolemma ion channel function (e.g. Na+-K+ pump) of the 
cardiomyocyte is preferentially fueled by glycolytic ATP production (28, 29). The 
functional compartmentalization is achieved through the location of key enzymes in the 
membrane or adjacent cytoskeleton region of cell (30). Loss of ionic homeostasis, either 
at the sarcolemma, or at the mitochondrial inner membrane is associated with irreversible 
cellular damage. In this view, continued glycolytic metabolism may represent a key 
requisite for cellular survival.   
In summary, we show that HIF-1α upregulates and prolongs glycolytic flux in 
heart for longer periods (i.e. 30 mins) of ischemia via activating gluconeogenesis. The 
preservation of glycogen in the HIF-1α heart provides uninterrupted anaerobic energy 
supply that primarily fuels ionic homeostasis and, which may prevent cardiomyocyte injury 
mediated by ionic gradient dissolution in ischemia.   
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ABSTRACT 
As the largest endocrine organ, adipose tissue secretes many bioactive molecules that 
circulate in the blood, collectively termed adipokines.  Efforts to identify such metabolic 
regulators have led to the discovery of a family of secreted proteins, designated as C1q 
tumor necrosis factor (TNF)-related proteins (CTRPs). The CTRP proteins, adiponectin, 
TNF-alpha, as well as other proteins with the distinct C1q domain are collectively 
grouped together as the C1q/TNF superfamily. Reflecting profound biological potency, 
the initial characterization of these adipose tissue-derived CTRP factors finds wide-
ranging effects upon metabolism, inflammation, and survival-signaling in multiple tissue 
types. CTRP3 (also known as CORS26, cartducin, or cartonectin) is a unique member 
of this adipokine family. In this review we provide a comprehensive overview of the 
research concerning the expression, regulation, and physiological function of CTRP3.  
INTRODUCTION 
Since the discovery of Leptin in 1994 and then later adiponectin there has been 
a fundamental shift in how adipose tissue is viewed within the medical and research 
community, as an active endocrine organ which effects human health and physiology 
(57, 87). In 2004 Wong et al. characterized a novel family of adipose tissue-derived 
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cytokines, collectively called adipokines, referred to as Complement C1q Tumor 
necrosis factor-Related Proteins (CTRPs) (76), like adiponectin and tumor necrosis 
factor (TNF) these CTRPs all contain a C1q globular domain and are characterized 
together as the C1q/TNF superfamily (62). To date, this superfamily has been 
documented to have a wide range and opposing effects on metabolism, food intake, 
inflammation, tumor metastasis, apoptosis, vascular disorders, ischemic injury, and 
even sexual reproduction (7, 8, 25, 29, 30, 49, 51, 57, 62, 64, 68, 69, 74-76, 81, 84, 89). 
The purpose of this review is to carefully summarize the research that has been 
accomplished on one of these proteins, CTRP3. A list of abbreviations used in this 
article is found in Table 3.1. 
Table 3.1: Abbreviations 
SP-1: specificity protein 1 
CTRP3: C1q TNF Related Protein 3 
LPS: Lipopolysaccharide 
TLR: toll-like receptor 
MCP-1: monocyte chemotactic protein 1 
PPAR: peroxisome proliferator-activated receptor 
pIgA: polymeric Immunoglobulin A  
RANKL: Receptor activator of nuclear factor kappa-B ligand 
TNF: Tumor necrosis factor 
IL-6: Interleukin-6 
AP-1: Activator protein 1 
c-FOS: Fos proto-oncogene  
Pit-1a: POU domain, class 1, transcription factor 1  
C/EBP-a/b: CCAAT-enhancer-binding proteins-alpha/beta  
MyoD: Myogenic Differentiation  
c-JUN: Jun proto-oncogene, AP-1 transcription factor subunit 
TY-IID: Transcription factor II D – “TATAA”  
CREB: cAMP response element-binding protein  
GATA-1: GATA-binding factor 1  
SRY: Sex-determining region Y  
Sox-5: SRY-related HMG-box 5  
c-Myc: similar to myelocytomatosis viral oncogene  
RXR: Retinoid X receptor  
PGC-1α: Peroxisome proliferators activated receptor-γ co-activator-1α  
NRF-1/NRF-2: nuclear respiratory factor 1/2  
TFAM: mitochondrial transcription factor A 
TBXAS1: thromboxane A synthase 1 
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HUVEC: Human umbilical vascular endothelial cells 
ROS:  Reactive oxygen species 
TGF-β: Transforming growth factor beta  
History of CTRP3 
Initial discovery 
CTRP3 was first discovered in 2001(43) in C3H10T1/2 mouse mesenchymal 
stem cells treated to induce chondrogenic differentiation. Because of its size and 23 
Gly-X-Y repeats in the N-terminal collagen domain it was originally named CORS26 
(Collagenous repeat-containing sequence 26 kDa protein). Later Wong et al. (2004) 
identified CTRP3 as a member of a family of highly conserved adiponectin paralogs 
designated as CTRPs and CORS26 was renamed CTRP3(76). Alternative names that 
have been used for CTRP3 are cartducin (1, 44) and cartonectin (56, 73), both due to 
the detection of CTRP3 expression in developing cartilage.  
Structure 
Analysis of the primary structure predicts that CTRP3 is a highly hydrophilic 
secreted protein, with an N-terminal hydrophobic signal peptide, and no transmembrane 
domains (43). Experimental work confirms that CTRP3 is a secreted protein and 
circulates in the blood, which indicates that the physiological function of CTRP3 occurs 
through endocrine mechanisms (51, 75). Additionally, CTRP3 has a series of N-terminal 
Collagenous repeats (Gly-X-Y), and a highly conserved C-terminal globular domain 
(76), thus placing CTRP3 within the expanding C1q TNF Superfamily (62) (Figure 3.1). 
CTRP3 shares sequence homology with adiponectin (38% in mouse and 36% in 
human), and is highly conserved (95.9% identity between human and mouse proteins) 
(36). Additionally, there are two splice variants of CTRP3 that have been identified. The 
longer splice variant, designated as CTRP3B, encodes an extra 73 N-terminal amino 
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acids due to the retention of intron 1. CTRP3B contains a highly conserved N-linked 
glycosylation site that is not present on the original splice variant, CTRP3A (51). At this 
time the functional significance of the splice variants of CTRP3 is unknown as research 
has focused almost exclusively on CTRP3A. Regardless, both CTRP3A and CTRP3B 
are secreted proteins which are detectable in human serum.  Although only CTRP3A 
has been detected in mouse serum, both variants are expressed in mouse adipose 
tissue (51, 75). One of the reasons for the difficulty in detecting the CTRP3B variant is 
that unlike CTRP3A, CTRP3B degrades rapidly unless it forms a higher order oligomer 
with CTRP3A (51). 
 
 
Figure 3.1:  Structural Overview of CTRP3. Two splice variants were identified and designated 
as CTRP3A and CTRP3B. B, organization of the CTRP3A and CTRP3B genes and proteins. 
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The human CTRP3A gene is 25.3 kb in size, consists of six exons and five introns, and is 
located on chromosome 5p13. Exons 1, 2, 3, 4, 5, and 6 of the CTRP3A gene are 171, 112, 
155, 130, 100, and 2,885 bp in size, respectively. The size of each intron is also indicated. Exon 
1B (gray square) contains a 219-nucleotide sequence found in CTRP3B cDNA, coding for an 
extra 73 amino acid residues. A potential N-linked glycosylation site is circled. The consensus 
splice donors are shown in italic type. This figure was originally published in The Journal of 
Biological Chemistry (51) and image reproduced according to the copyright policy of the 
ASBMB. 
CTRP3 is endogenously co-expressed in many tissues with other proteins 
within the C1q TNF superfamily. However, CTRP3 is unique as it does not form hetero-
oligomeric complexes with adiponectin or any other CTRP protein (76). Most CTRP 
proteins will form hetero-oligomers with adiponectin or at least 1 other CTRP protein 
when coexpressed (75, 76).  However, higher-order oligomers are the primary form by 
which CTRP3 is found circulating in either human or mouse serum, indicating that 
CTRP3 high-order oligomeric complexes occur solely between its two splice variants, 
CTRP3A and CTRP3B (51). While the significance of these posttranslational 
modifications and higher order structure formations have yet to be explored, it is likely 
that these modifications influence the function of CTRP3. Therefore, it is important to 
differentiate between functional studies and experimental findings gleaned from 
bacterial-produced compared with other types of recombinant CTRP3 protein. Bacterial-
produced recombinant CTRP3 protein does not possess the potentially physiologically 
relevant post-translational modifications or multimeric structures, and may explain any 
observed lack of biological activity (19, 61). 
Recently using the novel ligand-receptor capture method, and mammalian-cell 
expressed CTRP3, Li et al. (2016) (41) identified Lysosomal-associated membrane 
  43 
protein 1 (LAMP-1) and Lysosome membrane protein 2 (LIMP II) as potential receptors 
for CTRP3. Although it remains to be determined whether either of these proteins 
directly mediate the intercellular effects of CTRP3 or act as co-receptors for a yet 
unidentified protein, both LAMP1 and LIMPII are widely expressed in a number of 
different tissues corresponding to the variety of functions attributed to CTRP3. A 
comprehensive list of in vitro functions documented for CTRP3 is listed in Table 3.2. 
CTRP3 may also act without directly initiating intracellular action but rather through 
inhibiting the binding of other ligands. For example, lipopolysaccharide (LPS) is a 
potent endotoxin that binds to Toll-like receptor 4 (TLR4) and promotes a cellular 
inflammatory response. However, even though CTRP3 does not bind directly to either 
LPS or TLR4, CTRP3 prevents their interaction through an unestablished mechanism 
(30). 
Table 3.2: Complete Summary of the In Vitro Functions of CTRP3 
Cell line Citation Type of treatment Effect 
N1511 (mouse 
chondrogenic 
progenitor) 
Akiyama et 
al (2006)(1) 
10 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
Increased ERK ½, and Akt 
phosphorylation from 5 min-1 
hour, but not JNK or p38 
MAPK 
MSS31 (mouse 
endothelial cells) 
Akiyama (2) 
et al (2007) 
1-5 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
↑ Proliferation and migration, ↑ 
ERK1/2 & MAPK p38 within 
15 minutes. 
LM8 (mouse 
osteosarcoma cell 
line)  
Akiyama et 
al (2009)(3) 
2-10 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
CTRP3 treatment ↑ 
proliferation and ↑ ERK1/2 
phosphorylation with no effect 
on migration or p38, JNK1/2, 
or Akt phosporylation.  
NOHS (mouse 
osteosarcoma cell 
line)  
Akiyama et 
al (2009)(3) 
2-10 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
CTRP3 treatment ↑ 
proliferation and ↑ ERK1/2 
phosphorylation with no effect 
on migration or p38, JNK1/2, 
or Akt.  
Rat vascular 
smooth muscle 
cells (VSMCs) 
Feng et al 
(2016)(15) 
Human globular CTRP3 
(Aviscera Bioscience) Catalog 
# not reported 
CTRP3 promotes ATP 
synthesis, oxidative 
phosphorylation complex 
proteins, and 
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ROS levels; whereas siRNA 
knockdown 
reduces ATP and oxidative 
phosphorylation 
complex proteins levels 
Human primary 
colonic lamina 
propria 
fibroblasts 
(CLPF) 
Hofmann et 
al 2011(21) 
Recombinant CTRP-3 (High 
Five insect cells) 
Significantly and dose-
dependently reduced LPS-
induced IL-8 secretion in CLPF 
within 8 hours after LPS 
exposure, whereas LPS-
induced IL-6 and TNF release 
was not affected. CTRP-3 
inhibited TGF-β production 
and the expression of CTGF 
and collagen I in CLPF, 
whereas collagen III expression 
remained unchanged.  
RWPE-1 prostate 
cells (ATCC 
Number CRL-
11609) 
Hou Et al. 
2015(23) 
Mammalian expressed CTRP3 
(3, 10, or 30 µg/ml) 
Increased cell number in a dose 
dependent manner at 24-72 
hours, and 10 µg/ml prevented 
apoptosis. Cytokeratin-19, 
GLRX3 and DDAH1 were 
upregulated and cytokeratin-17 
and 14-3-3 sigma were 
downregulated proteins in 
CTRP3-treated cells. 
bone marrow 
macrophages 
(BMM) 
Kim et al 
(2015)(27) 
Recombinant human CTRP3 
was purchased from AdipoGen 
(Catalog number not reported) 
↓ osteoclast differentiation 
from BMM treated with IL-1, 
1,25(OH2)D3, Receptor 
activator of nuclear factor 
kappa-B ligand (RANKL), 
further CTRP3 prevented 
mature osteoclasts from 
reabsorbing bone 
Adipocyte (3T3-
L1) 
Kopp et al. 
2010(30) 
1-10 µg/ml Recombinant full 
length CTRP3 (H5 insect 
cells) 
Suppressed LPS, lauric acid, 
TLR1/2, or TLR3 ligand-
induced MCP-1 release.  
CTRP3 had no effect on 
TLR2/6 ligand-induced MCP-1 
release. Further, siRNA 
knockdown of CTRP3 
increased MCP-1 release and 
decreased adiponectin secretion 
and reduced lipid 
accumulation. 
Primary Human 
monocytes  
Kopp, A. et 
al.(2010)(30
)  
1 µg/ml Recombinant full 
length CTRP3 (H5 insect 
cells) 
Suppressed LPS-induced MIF 
& CCL4 release in lean 
subjects, & MCP-1 in 
monocytes from both diabetic 
and leans subjects. Prevents 
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Lauric acid induced release of 
IL-6 and TNF 
Primary Human 
monocytes  
Kopp, A. et 
al.(2010)(31
) 
1 µg/ml Recombinant full 
length CTRP3 (H5 insect 
cells) 
↓ LPS-induced secretion of IL-
6 in monocytes from control 
but not T2D. CTRP3 did not 
significantly affect TNF 
secretion. 
Adipocyte (3T3-
L1) 
Li et al 
2014(38) 
Recombinant CTRP3 (uncited 
origin) 
increased adipocyte glucose 
uptake and decreased TNF and 
IL6 secretion in insulin 
resistant 3T3-L1A 
Adipocyte (3T3-
L1) 
Li et al 
2014(39) 
Mammalian expressed 
recombinant CTRP3 (250 
ng/mL) 
↑ the secretion of adiponectin, 
leptin, visfatin,  and  apelin 
with peak detectable effect at 
12 hours (effects prevented by 
the addition of an AMPK 
inhibitor). 
Adipocyte (3T3-
L1) 
Schmid et al 
(2012)(59) 
siRNA knockdown of CTRP3  Reduced resistin secretion and 
lipolysis. 
Adventitial 
fibroblasts 
Lin et al 
(2014)(42) 
CTRP3  protein  (10 µg/ml) 
(source/type of CTRP3 was 
not reported) 
CTRP3 prevents TGF-β1 
induced fibroblasts phenotypic 
Conversion, proliferation, 
migration, collagen I 
expression, and connective 
tissue growth factor (all 
indicators of inappropriate of 
vascular remodeling and 
neointima formation).  
HSC-2/8 (human 
chondrocytes) 
Maeda et al 
(2006)(44) 
10 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
Increase proliferation 
N1511 (mouse 
chondrogenic 
progenitor) 
Maeda et al 
(2006)(44) 
2-10 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
Increase proliferation 
TM3 mouse 
Leydig Cells 
Otani et al 
(2012)(47) 
Mammalian expressed full 
length (3-30 ug/ml) 
Dose responsive ↑ testosterone 
production, ↑ steroidogenic 
acute regulatory protein mRNA 
and protein levels 
Adipocyte (3T3-
L1) 
Schmid et al 
2012(59) 
siRNA knockdown of CTRP3 siRNA knockdown of CTRP3 
reduced resistin secretion and 
lipolysis.  
Adipocyte (3T3-
L1) 
Schmid et al 
2013(58) 
siRNA-mediated cellular 
knockdown of CTRP-3 
siRNA-mediated cellular 
knockdown of CTRP-3 in 
adipocytes resulted in an 
upregulation of CTRP-5 
expression. 
Adipose tissue 
collected from 
control (n=3) or 
Schmid et 
al. 
(2012)(59) 
 CTRP3 protein levels were 
higher in subcutaneous 
adipocytes from an obese 
compared with lean donor, no 
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diabetic (n=3) 
female donors) 
differences were observed from 
visceral adipocytes. (Note: 
small sample size, n=3) 
THP-1 (human - 
Acute Monocytic 
Leukemia cell 
line) 
Weigert et 
al 2005(70) 
1 µg/ml Recombinant full 
length CTRP3 (H5 insect 
cells) 
Suppressed LPS induced: IL-6 
& TNF mRNA and release. 
Adipocyte (3T3-
L1) 
Wolfing et 
al 
(2008)(73) 
10 ng/ml Recombinant full 
length CTRP3 (H5 insect 
cells) 
increase adiponectin and 
resistin secretion but not 
promoter activity with no effect 
on IL-6 (no effect on human-
derived adipocytes).  
Primary cultured 
adult rat cardiac 
fibroblast (CF) 
Wu et al 
2015(77) 
2 µg/ml Recombinant human 
gCTRP3 (Aviscera  
Bioscience; 00082-01-100; E. 
Coli expressed); also used 
siRNA knockdown of CTRP3 
Inhibited TGF-β1α-induced α-
SMA, SM22α, SM22α, 
collagen I, collagen III, and 
connective tissue growth factor 
(CTGF) expression [markers 
for myofibroblast 
differentiation]. Whereas, 
SiRNA knockdown of CTRP3 
increased TGF-β1-induced α-
smooth muscle actin (α-SMA)  
and smooth muscle 22α 
(SM22α) collagen I, collagen 
III, and CTGF expression. 
Further CTRP3 attenuated 
TGF-β1 induced-elevations in 
phosphor-Smad3 (Ser204).  
 
Cardiomyocytes 
(adult mouse)  
Yi et al 
(2012)(81) 
Bacterial expressed globular 
domain of Mouse CTRP3 
CTRP3 upregulated levels of 
phosphorylated Akt, HIF1α, 
and VEGF.  Further 
cardiomyocyte hypoxia-
induced apoptosis was 
attenuated with condition 
media from 3t3-L1A 
adipocytes, however this effect 
was abolished when the 
conditioned media came from 
3T3-L1a cells treated with 
CTRP3 siRNA.  
human umbilical 
vascular 
endothelial cells 
(HUVECs) 
Yi et al 
(2012)(81) 
Bacterial expressed globular 
domain of Mouse CTRP3 
CTRP3 had no effect on tube 
formation, Akt phosphorylation 
or HIF1α or VEGF expression. 
These results suggest that the in 
vivo proangiogenic effect of 
CTRP3 is no through direct 
mechanisms on endothelial 
cells.  Further, treatment of 
HUVECs cell with condition 
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media from primary 
cardiomyocytes treated with 
CTRP3 significantly enhanced 
HUVEC tube formation. 
Primary meckel’s 
cartilage 
Yokohama-
Tamaki et al 
(2011)(82) 
Knock-down of CTRP3 
(antisense 
ogliodeoxynucleotide) 
Caused severe curvature 
deformation and suppressed 
growth. 
human mesangial 
cells (HMCs)  
Zhang et al 
(2016)(86) 
Full length human CTRP3 
(PubMed No. NM_030945.2) 
adenovirus mediated 
overexpression  
↓  pIgA-induce IL-6 and TGF-
beta secretion from HMC cells. 
Neonatal rat 
ventricular 
myocytes 
Zhang et al 
2016(85) 
0.5 – 4 µg/ml Human 
recombinant globular and full-
length CTRP3 (Aviscera 
Bioscience) Catalog # not 
reported 
Both increased the expression 
of PGC-1α, nuclear respiratory 
factor 1&2, and markers of 
mitochondrial biogenesis 
Human mesangial 
cells (HMCs) 
Zhang et al 
(2016)(86) 
Treated with Serum polymeric 
IgA (pIgA) from control or 
IgAN patients  
pIgA markedly increased IL-6 
and TGF-β in HMCs, which 
were suppressed after Ad-
CTRP3 transfection. 
Rat Cultured 
Carotid Arterial 
Rings 
Zhou et al 
(2014)(90) 
(1, 2, and 4 µg/mL) 
Recombinant  human  globular  
domain  CTRP3  Aviscera  
Bioscience  (00082-01-100,   
Santa Clara, CA) 
CTRP3 Promotes Vascular 
Calcification in  
High-Phosphate Cultured 
Carotid Arterial Rings. 
Rat vascular 
smooth muscle 
cells (VSMCs) 
Zhou et al 
(2014)(90) 
(1, 2, and 4 µg/mL) 
Recombinant  human  globular  
domain  CTRP3  Aviscera  
Bioscience  (00082-01-100,   
Santa Clara, CA) 
CTRP3 Promotes β-
Glycerophosphate–Induced  
VSMC Calcification In Vitro 
and promoted the phenotypic  
transition  from  contractile  to  
osteogenic  phenotype. CTRP3 
increases mitochondrial 
Reactive oxygen species levels 
in VSMC. 
 
Regulation 
Analysis of the upstream untranslated region for CTRP3 identified a number of 
putative consensus sequences for transcription factor regulation of CTRP3 expression. 
The proximal region of the CTRP3 promoter is highly conserved between rodent and 
human (28), indicating that there are conserved functional regulation sites. These 
predicted regulatory sites include loci for the following transcription factors: specificity 
protein 1 (SP-1); Activator protein 1 (AP-1); Peroxisome proliferator-activated receptor 
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(PPAR); Fos proto-oncogene (c-FOS); POU domain, class 1, transcription factor 1 (Pit-
1a); CCAAT-enhancer-binding proteins-alpha/beta (C/EBP-α/β); Myogenic 
Differentiation (MyoD); c-JUN; Transcription factor II D – “TATAA” box (TY-IID); cAMP 
response element-binding protein (CREB); GATA-binding factor 1 (GATA-1); Sex-
determining region Y (SRY); SRY-related HMG-box 5 (Sox-5); similar to 
myelocytomatosis viral oncogene (c-Myc); and Retinoid X receptor (RXR) (53-55). 
However, to date, only a few transcription factors have been demonstrated to regulate 
CTRP3 expression experimentally: c-FOS, SP-1, c-JUN, and PPAR-gamma. 
Although CTRP3, SP-1 and PPAR-gamma are induced during adipocyte differentiation, 
promoter activity assays demonstrate that PPAR-gamma, SP-1, and c-FOS are all 
negative regulators of CTRP3 expression (53, 56). Electrophoretic mobility shift assays 
confirmed that both SP-1 and PPAR-gamma (but not SRY, c-FOS, C/EBPβ, or PPAR-
alpha) bind to the promoter region for CTRP3. To date only the transcription factor c-
Jun has been shown to be an unequivocal positive regulator for CTRP3 transcription 
(28). The transcription factor c-Jun is one of three Jun family proteins making up the 
activator protein-1 (AP-1) transcription factor group. Chromatin immunoprecipitation 
assay confirmed that c-Jun binds to the AP-1 region (-184/-177) of CTRP3 (28), 
whereas, other Jun and Fos members JunB, JunD, FosB, Fra-1 and Fra-2 were tested 
by a reporter gene assay and had no effect on CTRP3 promoter activity (28). Further, 
treatment of adipocytes, in vitro, or diet-induced obese rats, in vivo, with the glucagon-
likepeptide-1 (GLP-1) receptor agonist, Exendin-4 (Ex-4), increased CTRP3 expression 
and circulating levels through activation of the Protein kinase A (PKA) pathway (37, 40). 
Briefly, the activation of GLP-1 receptor and, the PKA pathway activates a HOB1 motif 
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within the A1 activation domain of c-JUN and promotes c-JUN’s binding to the AP-1 
region (6). However, the regulation of CTRP3 under physiological conditions in vivo has 
not yet been established. Unlike most adipokines, circulating CTRP3 levels are 
increased with fasting (51), indicating that CTRP3 levels may be suppressed by either 
insulin or activated by glucagon signaling pathways. Further, CTRP3 levels are 
negatively associated with insulin and leptin levels in high fat fed mice (51). Taken 
together, these data show a potential reciprocal relationship between food intake and 
CTRP3. However, the clinical implications have yet to be explored, especially regarding 
the significance of the by-phasic regulation of CTRP3 and lipid metabolism.  
Tissues expressed  
A summary of cell lines, which express CTRP3, in vitro, are listed in Table 3.3. 
CTRP3 is not detectable in undifferentiated adipocytes, but can be detected at 4 days of 
differentiation (55, 56). These data match in vivo data which shows that CTPR3 is highly 
expressed in adipose tissue. In addition, CTRP3 is also detected during development, 
starting at mouse embryonic day 15 (43, 75, 76), in developing chondrocytes (43) and 
cartilage (44). These data have led to speculation that CTRP3 is essential for 
appropriate bone growth and development. This is supported by experimental evidence 
that demonstrates that CTRP3 stimulates the proliferation and differentiation of 
chondrogenic and osteogenic precursors, inhibits osteoclast activity, and is essential for 
appropriate bone formation in vitro (1, 27, 44, 82). However, a clinical association 
between abnormal development and deregulation of CTRP3 protein has yet to be 
documented. On the other hand, CTRP3 is highly expressed in both osteoscarcoma 
and chandroblastoma cell lines but not in the MC3T3-E1 mouse osteoblast-like non-
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cancer cell line (3). These data have led to speculation that elevated CTRP3 level in 
adults may be a risk factor and/or biomarker for certain types of cancer, specifically 
osteoscarcoma, but again this hypothesis remains to be tested either in vivo or in a 
clinical population. 
Table 3.3: CTRP3 Expression In Vitro 
Cell Line Reference Finding 
Adipose tissue 
collected from 
control (n=3) or 
diabetic (n=3) female 
donors 
N1511 (mouse 
chondrogenic 
progenitor) 
Schmid et 
al 
2012(59) 
 
 
Maeda et 
al 
2006(44) 
CTRP3 protein levels were higher in subcutaneous adipocytes from 
an obese 
compared with lean donor, no differences were observed from 
visceral 
adipocytes. (Note: small sample size, n = 3) 
 
 
CTRP3 is induced w/ differentiation by TGF-beta 
3T3-L1a (mouse pre-
adipocyte) 
Schaffler 
et al 
2007(56) 
Produce CTRP3 at day 4 differentiation and CTRP3 promoter 
activity was suppressed when treated with PPAR ligands: 
troglitazone (α/g), fenofibrate (α), but not 15-Deoxy-Delta-12,14-
prostaglandin J2.  
3T3-L1a (mouse pre-
adipocyte) 
Li et al 
2015(37) 
Exendin-fragment 4 (Ex-4), a specific GLP-1 receptor agonist, 
specifically used to treat T2D, increased CTRP3 mRNA and protein 
whereas Ex-9 (and GLP-1 antagonist) or blocking activation of 
PKA (thr197) phosphorylation by H89, a selective antagonist of 
PKA, blocked Ex-4 induced increases in CTRP3. Neither H89 nor 
Ex-9 had any effect on CTRP3 alone.  
3T3-L1a (mouse pre-
adipocyte)  
Schmid et 
al 
2012(59) 
CTRP3 is positively regulated by insulin, and inhibited by chronic 
LPS-exposure or Intracellular infection of adipocytes by S. aureus. 
Further, siRNA knockdown of CTRP3 reduced resistin secretion 
and lipolysis.  
MC3T3-E1 (mouse 
osteoblast-like cell 
line; non-cancer) 
Akiyama 
et al 
2009(3) 
Neither CTRP3 mRNA or protein was detected 
Human mesangial 
cells (HMCs)  
Zhang et al 
2016(86) 
polymeric IgA (pIgA) suppressed CTRP3 mRNA and protein 
whereas the IgA1 fractions (mIgA and pIgA) had no effect on 
CTRP3.  Further, galactose-deficient IgA (gd-IgA; the type of IgA 
found in IgAN patients) suppressed CTRP3 mRNA levels even 
more than pIgA at identical concentrations (~60% compared with 
30%).   
LM8 (mouse 
osteosarcoma cell 
line)  
Akiyama 
et al 
2009(3) 
CTRP3 mRNA and protein detected.  
NOHS (mouse 
osteosarcoma cell 
line)  
Akiyama 
et al 
2009(3) 
CTRP3 mRNA and protein detected. 
Human omental 
adipose tissue 
explants 
Tan et al 
2013(65) 
Metformin increased CTRP3 secretion. 
TM3 mouse Leydig 
Cells 
Otani et al 
2012(47) 
Express CTRP3 
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In adult mice CTRP3 is considered an adipokine, as it is predominantly 
expressed in adipose tissue (55, 56, 75), indicating that CTRP3 may have a functional 
role in energy storage and metabolism. However, CTRP3 is also expressed in the lung, 
kidneys, spleen, testis, and macrophages with moderate expression in heart, bone, 
small intestine, liver, kidney, skeletal muscle, and vascular smooth muscle cells (1, 43, 
44, 47, 51, 54, 59, 75, 76, 90). Combined these data indicate that CTRP3 has a variety 
of factors which could contribute to its regulation and function.  In the following sections 
we will detail the experimental evidence regarding the functional activity of CTRP3 in 
regards to metabolism, cardiovascular health, inflammation, and growth and 
development. 
Metabolism, Metabolic disease and CTRP3 
Overview 
CTRP3 has been documented to have a variety of effects on metabolism. The 
complete overview of in vitro effects is listed in Table 3.2. Briefly, CTRP3 increases 
adipokine secretion, attenuates inflammatory signaling, promotes proliferation, 
increases cellular differentiation, and increases hepatic lipid oxidation (39, 41, 50, 51, 
58). Whereas, the in vivo the effects of CTRP3 are less well examined. The summary of 
all animal experiments and CTRP3 are listed in Table 3.4. For example, in rodents an 
acute injection with recombinant CTRP3 protein decreases serum glucose levels for up 
to 8-hours with no change to insulin levels (51). The chronic transgenic overexpression 
of CTRP3 had not effect upon glucose levels, which demonstrates the development of a 
potential compensatory mechanism (51). On the other hand, both transgenic 
overexpression and daily administration of CTRP3 were effective in attenuating high fat 
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diet-induced hepatic insulin resistance and hepatic steatosis (50). Conversely, hepatic 
triglycerides were elevated in high fat-fed CTRP3 Knockout mice when compared to 
high fat-fed wild-type mice (71). Considered together, these data suggest that the 
metabolic effects of CTRP3 are specific to the liver, as no changes to metabolism were 
observed in skeletal muscle in any experimental (in vivo or in vitro) model examined. 
Interestingly, neither transgenic overexpression nor genetic deletion of CTRP3 resulted 
in a measurable metabolic effect in mice fed a low fat diet (50, 71), which indicates that 
CTRP3 may function specifically to help regulate metabolism in response to elevated 
lipid consumption. 
Table 3.4: Metabolic Effects of CTRP3 In Vivo 
Model Reference Results 
Male rats HFD+low 
dose Streptozotocin 
Li et al 2014(40) CTRP3 mRNA increased between birth and 10 
weeks of age. Insulin resistance or T2D 
decreased CTRP3 (Protein &mRNA) and 
treatment with Ex-4 slightly increased CTRP3.  
CTRP3 Knockout and 
collagen-induced 
arthritis model 
Murayama et al 
(2014)(46) 
↑ severe histopathological changes.  
Transgenic CTRP3 
overexpression with 
low or high fat diet 
Petersen et al 
(2016)(48) 
LF-diet; ↑ the circulating levels of CCL11, 
CXCl9, CXCL10, CCL17, CX3CL1, CCL22, 
AND Scd30. 
HF-Diet: ↓ circulating levels of IL-5, TNF-α, 
sVEGF2, and sVEGFR3, and ↑ circulating 
levels soluble gp130. 
Acute injection of 
CTRP3 
Peterson et al 
(2010)(50) 
↓glucose, ↑pAkt  and hepatic gluconeogenesis 
(specifically PEPCK and G6Pase. 
Transgenic CTRP3 
overexpression with 
low or high fat diet 
Peterson et al 
(2012)(51) 
No metabolic effect LF-diet; On HF-diet: mild 
shift to lipid oxidation, ↓ hepatic triglyceride 
synthesis, ↓ hepatic stenosis, ↑ insulin 
sensitivity. ↓ circulating TNF, IL5 and 
cholesterol levels and more than doubled 
soluble gp130 (sgp130) levels (an inhibitor of 
IL-6).  
Viral suspension 
consisting of 1x10^9 
genomic copies of the 
lentivirus-CTRP3 
(Lenti-CTRP3) 
Wang et al 
(2016)(67) 
Attenuates Brain Injury after Intracerebral 
Hemorrhage via AMPK-Dependent Pathway in 
Rat. 
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CTRP3 Knockout fed 
a high fat diet 
Wolf et al (2016)(71) No differences in metabolic factors between KO 
and WT, however the liver was smaller with a 
higher triglyceride content. 
Mouse model of 
myocardial infarction 
(MI); Adenovirus 
mediated 
overexpression of 
human full-length 
CTRP3 
Yi et al 2012(81) MI reduced adipocyte CTRP3 mRNA and 
plasma protein levels.  Whereas, Replenishment 
of CTRP3 after MI Improves Survival, Cardiac 
Function, promotes angiogenesis, 
 
Regardless, the clinical implications of these effects have yet to be explored, as 
the reported associations between obesity and/or type 2 diabetes (T2D) with CTRP3 
levels are contradictory in the literature. The summary finding of all cross sectional 
human studies, which examine CTRP3 levels, are listed in Table 3.5.  Briefly, CTRP3 
levels are reported to be elevated (12), not different (16, 66), or reduced (5, 14, 52, 65, 
72, 83) with obesity and/or T2D.  In most reports circulating CTRP3 levels are higher in 
women than in men (10, 14, 72, 83), with one exception (52). Further complicating the 
relationship between CTRP3 levels and human health, Wager et al. (2016) (66) 
reported that CTRP3 levels are elevated with obesity in male but are reciprocally 
reduced with obesity in female subjects.  This contradictory gender dependent 
association of obesity and circulating CTRP3 levels provides some explanation 
regarding the conflicting data in the literature, as almost all the reported studies 
combined varying proportions of male and female subjects within each experimental 
group. Nevertheless, these data demonstrate that there is a gender specific regulation 
and function of CTRP3 that needs to be explored in more detail. Further, all of these 
studies have examined the total amount of CTRP3 with no attention being given to the 
different splice variants or in the multimeric structures of the circulating CTRP3. This is 
worth noting as high molecular weight adiponectin is thought to be the active form (20, 
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32), and similarly the different splice variants and multimeric structure may also 
contribute to the function of CTRP3. Lastly, the associations between circulating CTRP3 
levels (splice variants and multimeric structures) and hepatic steatosis in human 
subjects have not been explored even though animal experiments have shown a 
specific hepatic effect of both CTRP3A and CTRP3B (51). 
Table 3.5: Cross-Sectional Studies Regarding CTRP3 Levels 
Population 
(Male:Female) 
Referenc
e 
Result 
Newly diagnosed T2D 
(25:22) vs Control (35:28) 
Ban et al 
2014(5) 
CTRP3 levels were lower in T2D (150 ng/ml) vs control (249 
ng/ml). CTRP3 was negatively associated with C-reactive protein 
levels and positively associated with insulin levels in control 
subjects.  No associations were observed in T2D.  
126 singleton live births 
(67:59) 
Chen et 
al. 
2016(9) 
CTRP3 was positively correlated with Ponderal index (a 
measurement of thinness) and birth weight.  
Control (40:79), 
prediabetic (40:71), or 
T2D (54:65)  
Choi et al 
2012(12) 
Overall: CTRP3 levels were positively correlated with Total 
cholesterol, fasting blood glucose, AST and ALT, Creatinine, and C-
reactive protein levels, and negatively correlated with estimated 
glomerular filtration rate. CTRP3 increased significantly with T2D 
(Normal 273, prediabetes 482, and T2D 516 ng/ml).  
453 nondiabetic Korean 
adults (137:316) 
 
Choi et 
al. 
2013(10) 
CTRP3 levels were higher in women than men. Independently 
associated with age, sex, and triglyceride, LDL cholesterol, 
adiponectin, and retinol-binding protein 4 (RBP4) levels. 
362 Korean adults: with 
acute coronary syndrome 
(49:20), stable angina 
pectoris (58:27), or control 
subjects (137:71) 
Choi et 
al. 
2014(11) 
CTRP-3 levels were lower in patients with acute coronary syndrome 
or stable angina pectoris compared to control subjects. CTRP-3 
levels negatively associated with glucose and C-reactive protein 
positively associated with HDL-cholesterol and adiponectin. 
   
Newly diagnosed obese 
and hypertensive patients 
(124:83) 
Deng et 
al 
2015(14)  
Regardless of groups women had higher CTRP3 levels than men. 
Both obesity and High blood pressure were associated with lower 
CTRP3 levels, there was no further reduction in obesity combined 
with High BP 
Obese (33:39) and  
T2D (34:35) 
Flehmig 
et al 
2014(16) 
No difference in CTRP3 levels with obesity or T2D. Of the 69 T2D, 
46 were taking metformin and CTRP3 levels were increased with 
metformin (267 vs 343 ng/mL).  
COPD patients (50:23) 
and  healthy controls 
(29:25) 
 
Li et al 
2015(34) 
CTRP3 levels (COPD 950 ng/mL; Control 820 ng/mL) had no 
correlation to lung function. No association between CTRP-3 and 
CRP, TNF-α, or adiponectin. 
Lean (25:20), obese 
(19:24), T2D (17:24), and 
Obese+T2D (22:23)    
Qu et al 
2015(52) 
No difference in CTRP3 between men and women (397.51 ± 122.67 
vs 416.17 ± 131.24 ng/mL,). CTRP3 levels were reduced in obese 
and T2D and further reduced in obese+T2D.  CTRP3 levels were 
negatively associated with IL-6 levels, HOMA-IR, and HbA1c.   
  55 
Women with Polycystic 
ovary syndrome (PCOS)  
Tan et al. 
2013(65) 
CTRP3 levels were lower in women with PCOS (200 ng/ml) 
compared with control (330 ng/ml); Metformin intervention 
increased CTRP3 levels to (272 ng/ml). BMI, Insulin, LDL, 
Triglycerides, CRP and Carotid intima-media thickness were all 
negatively associated with CTRP3 levels. TNF levels were not 
associated with CTRP3 
Lean (20:40) and obese 
(6:44)  
Wolf et 
al 
2015(72) 
CTRP3 was inversely associated with BMI and triglyceride levels. 
Men had significantly lower CTRP3 levels compared to women 
(397.7 vs. 432 ng/mL, p<0.01).  
Control (61:22) vs.  
metabolic syndrome 
(32:12)  
Yoo et 
al. 
2013(83) 
CTRP3 concentrations exhibit a significant negative association 
with cardiometabolic risk factors and positive association with 
adiponectin.  
16 patients diagnosed with 
IgA nephropathy (IgAN) 
compared to 12 controls 
Zhang et 
al 
2016(86) 
CTRP3 levels were lower in patients with IgAN (TGF-β and IL-6 
levels were elevated in these patients).  
Patients with symptoms 
requiring heart 
catheterization to 
diagnosis obstructive CAD 
(52:48) 
Wagner 
et al 
2016(66) 
No association between obstructive coronary artery disease and 
CTRP3 levels.  CTRP3 levels were higher in lean female than 
males. CTRP3 levels increased with obesity in males, but decreased 
with obesity in female patients.  
 
Human studies 
To date very few experimental intervention studies have been performed with 
human subjects. The first, Wurm et al. (2007) (78) examined circulating CTRP3 levels 
before and 2 hours after a glucose load (n=20, 14 males and 6 females) and observed 
no change. However, this study occurred before there were reliable ELISA’s developed 
for CTRP3 and examined CTRP3 levels solely though immunoblot analysis. Further 
complicating the results from this study is that although they reported the supplier (R&D 
Systems) they did not include the catalog number for the antibody used and they 
reported band migration of 50 kDa for CTRP3 on a denaturing SDS-PAGE. CTRP3 has 
a predicted and gel migration ~30 kDa and although the posttranslational modifications 
for CTRP3 could result in a higher than predicted migration pattern on an SDS gel, this 
has not been observed by other researchers (1, 43, 51, 70, 75). Indeed, the antibody for 
human CTRP3 from R&D Systems (R and D Systems Cat# AF7925, 
RRID:AB_2619735) also reports detecting a band at ~30 kDa. Moreover, using an 
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ELISA based method Ban et al. (2014) observed that in type 2 diabetic patients CTRP3 
levels decreased from ~150 to 50 ng/ml in response to a 2-hour oral glucose load (5). In 
light of these data and the progress within the past 9 years in CTRP3 antibody and 
ELISA development, the effects of glucose on CTRP3 levels in a healthy human subject 
population should be reexamined. In addition, due to the potential role of CTRP3 in lipid 
metabolism, experiments should also examine the effects of acute lipid loading 
on circulating CTRP3 levels. 
Only one study has examined the effects of exercise on circulating CTRP3 
levels in human subjects.  Briefly, Choi et al. (2013) examine changes to circulating 
CTRP3 levels after a 3-month exercise program (45 min cardio/20 min resistance 
5x/week) in 76 obese Korean females. (10) They found that CTRP3 levels decreased by 
~15% (444 ng/ml to 374 ng/ml) after exercise intervention. The exercise training 
program also resulted in ~9% loss in body weight, so it is unclear if the change in 
CTRP3 levels were due to exercise or the reduction in body fat. The effects of acute 
exercise or exercise training on CTRP3 levels in a healthy human population or in the 
absence of weight loss have not been investigated.  
Lastly, Tan et al. (2013) (65) reported that women with polycystic ovary 
syndrome had lower levels of CTRP3 than control subjects.  Polycystic ovary syndrome 
is an endocrine system disorder associated with obesity, diabetes, dyslipidemia, and 
cardiovascular complications and Metformin is a common medication used in the 
treatment of insulin resistance, obesity and type 2 diabetes. CTRP3 levels were 
restored with Metformin treatment along with general improvement in insulin sensitivity. 
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CTRP3 and Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause of death in the world, 
accounting for 30% of all deaths. (17) The identification of novel biomarkers indicating 
the progression, or signaling pathways which can be exploited as a treatment, for CVD 
is an ongoing interest for combating this disease. It is well established that obesity is a 
leading risk factor for CVD (63), however very little attention has been given to the 
endocrine function of adipose tissue and its role in CVD.  In both cell culture and animal 
models CTRP3 has been shown to be protective following heart attack (myocardial 
infarction, MI) or stroke (intracerebral hemorrhage, ICH) (11, 42, 67, 77, 80, 81, 83, 89). 
Table 3.6 contains the complete summary of the treatment effects of CTRP3 treatment 
as it related to CVD. Specifically, CTRP3 stimulates mitochondrial biogenesis in cardiac 
tissue and promotes vascular relaxation (85,89), whereas immediately following an MI 
there is a significant decrease of adipose tissue CTRP3 mRNA and circulating CTRP3 
protein levels (77, 81). In animal models of MI exogenous CTRP3 pretreatment 
(adenovirus-delivered or recombinant CTRP3) increases survival, improves postevent 
cardiac function, and prevents pathological remodeling (77, 81). Progressive remodeling 
after myocardial infarction (MI) is a leading cause of morbidity and mortality associated 
with MI. Specifically Transforming growth factor beta (TGF-β) has been reported to be 
involved in ventricular remodeling by promoting myocardial fibrosis (88). However, 
CTRP3 attenuates TGF-β1-induced signaling and pathogenic remodeling post-MI both 
in vivo and in vitro (77). Regarding stroke recovery, preconditioning with CTRP3 
reduced cerebral edema, reduced blood-brain barrier damage, improved neurological 
  58 
function, and reduced oxidative stress following ICH (67,80). Collectively, these data 
illustrate the potential of CTRP3 and CTRP3-mediated signaling pathways as a 
prospective post-MI/ICH treatment targets. 
Table 3.6: Summary of Cardiovascular Effects of CTRP3 Treatment 
Model Referenc
e 
Treatment/Measurement Effect 
MSS31 (mouse 
endothelial 
cells(79)) 
Akiyama 
(2) et al 
(2007) 
1-5 µg/ml [E. Coli produced 
His6-tagged signal peptide 
removed] 
↑ Proliferation and migration, ↑ ERK1/2 & 
MAPK p38 within 15 minutes.  
Rat vascular 
smooth muscle 
cells (VSMCs) 
Feng et 
al 
2016(15) 
Recombinant human 
globular CTRP3 (Aviscera 
Bioscience, no catalog # 
provided), or siRNA 
knockdown of CTRP3  
CTRP3 increase ATP synthesis and oxidative 
phosphorylation complex proteins, reversed 
with knockdown. CTRP3 increases 
mitochondrial ROS.  
Rat vascular 
smooth muscle 
cells (VSMCs) 
Feng et 
al 
2016(15) 
Recombinant  human 
globular  domain CTRP3 
(Aviscera Bioscience, no 
catalog # provided) 
CTRP3 increases mitochondrial Reactive 
oxygen species levels in VSMC. 
Adventitial 
fibroblasts 
Lin et al 
2014(42) 
CTRP3  protein  (10 µg/ml) 
(source/type of CTRP3 was 
not reported) 
CTRP3 prevents TGF-β1 induced fibroblasts 
phenotypic conversion, proliferation, 
migration, and collagen I expression.  
Primary 
cultured adult 
rat cardiac 
fibroblast (CF) 
Wu et al 
2015(77) 
2 µg/ml Recombinant 
human gCTRP3 (Aviscera  
Bioscience; 00082-01-100; 
E. Coli expressed); also 
used siRNA knockdown of 
CTRP3 
CTRP3 inhibited TGF-β1 induced markers for 
myofibroblast differentiation and TGF-β1 
induced- phosphorylation of Smad3. Whereas, 
CTRP3 knockdown increased TGF-β1 
induced markers for myofibroblast 
differentiation.  
Rat 
intracerebral 
hemorrhage 
(ICH) 
Yang et 
al 
2016(80) 
+/- lentivirus or 
recombinant CTRP3 (80 
µg/kg, Chimerigen, USA), 
Reduced cerebral edema and blood-brain 
barrier damage and improved neurological 
functions and reduced oxidative stress via 
PKA signaling pathway 
Cardiomyocyte
s (adult mouse)  
Yi et al 
2012(81) 
Bacterial expressed globular 
domain of Mouse CTRP3, 
and condition media from 
3T3-L1a cell +/- CTRP3 
siRNA. 
CTRP3 upregulated levels of phosphorylated 
Akt, HIF1α, and VEGF. Cardiomyocyte 
hypoxia-induced apoptosis was attenuated 
with condition media from 3t3-L1A 
adipocytes, abolished with CTRP3 siRNA.  
HUVEC Yi et al 
2012(81) 
Bacterial expressed globular 
domain of mouse CTRP3 
Condition media from primary 
cardiomyocytes treated with CTRP3 
significantly enhanced HUVEC tube 
formation. No direct effect of CTRP3  
Mouse -
myocardial 
infarction (MI)  
Yi et al 
2012(81) 
Adenovirus or bacterial 
expressed globular domain 
of mouse CTRP3 
MI reduced CTRP3 levels, CTRP3 treatment 
improved survival rate, restored cardiac 
function, increased revascularization, and 
reduced fibrosis 
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Neonatal rat 
ventricular 
myocytes 
Zhang et 
al 
2016(85) 
0.5 – 4 µg/ml Human 
recombinant globular and 
full-length CTRP3 
(Aviscera Bioscience, no 
catalog #) 
CTRP3 increased AMPK activated 
transcription factors and restored hypoxia-
reoxygenation injury induced reduction in 
sirtuin1, PGC-1α, NRF-1, complex III and 
ATP content. 
Aortic rings 
from C57BL/6 
mice 
Zheng et 
al 
2011(89) 
mammalian expressed 
CTRP3 (1, 3, & 10 µg/ml) 
3 and 10 (but not 1) µg/ml of mammalian 
expressed CTRP3 caused significant 
vasorelaxation. 
Rat Cultured 
Carotid 
Arterial Rings 
Zhou et 
al 
2014(90) 
(1-4 µg/mL) human 
globular CTRP3  (Aviscera  
Bioscience, 00082-01-100) 
CTRP3 Promotes Vascular Calcification in 
High-Phosphate Cultured Carotid Arterial 
Rings. 
Rat vascular 
smooth muscle 
cells (VSMCs) 
Zhou et 
al 
2014(90) 
(1-4 µg/mL) human 
globular CTRP3  (Aviscera  
Bioscience, 00082-01-100) 
CTRP3 Promotes β-Glycerophosphate–
Induced VSMC Calcification and 
mitochondrial Reactive oxygen species levels 
in VSMC. 
Mouse: 
Adenine-
induced 
chronic renal 
failure (CRF) 
Zhou et 
al 
2014(90) 
CTRP3 levels measured by 
ELISA and RT-qPCR or 
Adenovirus  encoding  full-
length human CTRP3 
Protein CTRP3 levels increased but adipose 
mRNA expression was reduced with CRF. 
CTRP3 Increased Vascular Calcification. 
CTRP3 is also demonstrated to play a large role in angiogenesis and 
endothelial cell proliferation. (2, 23, 45, 81) For example, during the recovery period 
following rat carotid artery balloon-injury model CTRP3 expression increases 
dramatically (35). Interestingly CTRP3 may not act directly on the endothelial cells, but 
through indirect pathways mediated by cardiac or smooth muscles cells.  Direct 
treatment of Human Umbilical Vein Endothelial Cells (HUVEC) with CTRP3 had no 
direct effect on capillary-like structures formation (tube formation), Akt phosphorylation 
or hypoxia-inducible factor 1, alpha subunit (HIF-1α) or Vascular endothelial growth 
factor (VEGF) expression. (81) However, conditioned media from primary 
cardiomyocytes treated with CTRP3 induced HUVEC tube formation, indicating the 
presence of CTRP3-induced cardiomyocyte-secreted paracrine factors. (81)  However, 
the direct effect of CTRP3 on HUVEC cells cannot be completed ruled out as Yi et al. 
(2012) (81) used bacterial expressed CTRP3 directly on HUVEC cells and used 
mammalian expressed CTRP3 in vivo. This discrepancy may indicate a post-
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translational modification is required for CTRP3-induced effects on vascular 
endothelium.    
As shown in table 3.6, very few studies have examined the association between 
CVD and circulating CTRP3 levels in a human patient population.  Specifically, Wagner 
et al. (66) observed no association between the presence of CVD and CTRP3 levels 
among patients with symptoms requiring catherization for detecting the presence of 
coronary artery blockage. Whereas, Deng et al. 2015 (14), observed that both obesity 
and high blood pressure were associated with lower CTRP3 levels and Choi et al. 2014 
(11) reported that CTRP-3 concentrations in patients with acute coronary syndrome or 
stable angina pectoris were significantly decreased compared to control subjects.  
Further, CTRP3 concentrations have been shown to exhibit a significant negative 
association with many cardiometabolic risk factors (11, 83). As CTRP3 levels decrease 
with obesity, at least in men (66), the lower levels of CTRP3 may contribute to the 
impaired mitochondrial biogenesis in cardiac cells and increase the 
susceptibility/severity of an MI event. On the other hand, excessive sustained elevation 
of CTRP3 may also be detrimental to cardiovascular health as CTRP3 as promotes 
vascular and aortic ring calcification (90), increase vascular calcification promotes 
arterial hardening and the development of arteriosclerosis. Regardless of the 
associations between CTRP3-mediated signaling and CVD appear promising and need 
to be investigated in more detail. 
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Inflammation 
Metabolic syndrome is defined as a cluster of risk factors which directly 
increase the risk of CVD, T2D, and all-cause mortality (4, 26). One of the major defining 
risk factors for metabolic syndrome is a chronic state of low-grade inflammation state 
marked by elevated circulating pro-inflammatory cytokines (TNF, IL-6, and C-reactive 
protein). The adipose tissue immune response plays a major role in the development of 
the chronic pro-inflammatory state (22, 26). Whereas, CTRP3 is a potential anti-
inflammatory mediator, and is negatively associated with the pro-inflammatory cytokines 
TNF, IL-6, and C-reactive protein (5, 11, 12, 14, 48, 50, 52, 65, 83).  In animal models 
diet-induced obesity results in decreased CTRP3 levels concurrent with an elevation in 
TNF and IL-6 (50). Similarly, diet-induced obese CTRP3-knockout mice have an 
enhanced elevation of IL-6 and TNF levels (71). Further, transgenic overexpression of 
CTRP3 attenuates the high-fat diet induce rise in cytokine levels and more than doubles 
circulating soluble gp130 (sgp130) levels (50). Circulating sgp130 is a potent inhibitor of 
inflammatory cytokines such as IL-6 (24). On another note, although essential for 
regulating platelet aggregation, excessive levels of the cytokine thromboxane A2 are 
associated with the development of insulin resistance and arteriosclerosis (18), and are 
elevated in both human and mouse models of obesity (33). However, loss of 
Thromboxane synthase (TBXAS), the enzyme necessary to produce thromboxane A2, 
markedly enhances insulin sensitivity concurrent with the up-regulation of CTRP3, as 
well as other adipokines (CTRP9, CTRP12) (33). CTRP3 has also demonstrated 
potential as a treatment for a specific inflammatory disorder, IgA nephropathy (IgAN). 
IgAN is a kidney disorder caused by deposits of the protein immunoglobulin A (IgA) 
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inside the glomeruli of kidney and excessive mesangial cell activation. In patients with 
IgAN CTRP3 levels are significantly reduced and the cytokines IL-6 and TGF-β are 
elevated (86).  Treatment of isolated adult human mesangial cells (HMCs) with CTRP3 
reduced IL-6 and TGF-β production and inhibited HMC activation (86). Combined these 
data demonstrate the potential of CTRP3 in the treatment of inflammatory disorders. 
The summary finding of all studies examining the connection between inflammation and 
CTRP3 are listed in Table 3.7. 
Table 3.7: CTRP3 and Inflammation 
Model Referen
ce 
Type of treatment Effect 
Human primary 
colonic lamina 
propria 
fibroblasts 
(CLPF) 
Hofman
n et al 
2011(21
) 
Recombinant CTRP-3 
(High Five insect 
cells) 
Significantly and dose-dependently reduced 
LPS-induced IL-8 secretion in CLPF within 
8 hours after LPS exposure, whereas LPS-
induced IL-6 and TNF release was not 
affected. CTRP-3 inhibited TGF-β 
production and the expression of CTGF and 
collagen I in CLPF, whereas collagen III 
expression remained unchanged.  
Primary Human 
monocytes  
Kopp et 
al 
2010(30
)  
1 µg/ml Recombinant 
full length CTRP3 
(H5 insect cells) 
Suppressed LPS-induced MIF & CCL4 
release in lean subjects, & MCP-1 in 
monocytes from both diabetic and leans 
subjects. Prevents Lauric acid induced 
release of IL-6 and TNF 
Primary Human 
monocytes  
Kopp et 
al 
2010(31
) 
1 µg/ml Recombinant 
full length CTRP3 
(H5 insect cells) 
↓ LPS-induced secretion of IL-6 in 
monocytes from control but not T2D. 
CTRP3 did not significantly affect TNF 
secretion. 
Adipocyte 
(3T3-L1) 
Li et al 
2014(38
) 
Recombinant CTRP3 
(uncited origin) 
Decreased TNF and IL6 secretion in insulin 
resistant 3T3-L1A. 
Transgenic 
CTRP3 
overexpression 
and CTRP3 
Knockout  
Peterse
n et al 
2016 
(48) 
Response to sublethal 
dose of LPS challenge 
No effect on IL-1β, IL-6, TNF-α, or MIP-2 
induction. 
LPS (1 µg i.p.) 
into male mice 
+/- CTRP3 
Schmid 
et al. 
2014 
(60) 
Recombinant CTRP-3 
(H5 insect cells) 
Intraperitoneal injection (but not IV) 
injection of CTRP-3 significantly reduced 
LPS-induced IL-6 and levels MIP-2.   
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16 patients 
diagnosed with 
IgA 
nephropathy 
(IgAN) 
compared to 12 
controls 
Zhang 
et al 
2016 
(86) 
 CTRP3 levels were lower in patients with 
IgAN (TGF-B and IL-6 levels were elevated 
in the patients). 
THP-1 (human 
- Acute 
Monocytic 
Leukemia cell 
line) 
Weigert 
et al 
2005 
(70) 
1 µg/ml Recombinant 
full length CTRP3 
(H5 insect cells) 
Suppressed LPS induced: IL-6 & TNF 
expression and secretion. 
Lipopolysaccharide (LPS), is a well-established endotoxin used as a model of 
systemic immune response, in vivo. In cell culture models LPS inhibits adipose tissue 
differentiation, induces insulin resistance, and prevents the expression of CTRP3 (59).  
Whereas, CTRP3 has been shown to specifically block the binding of LPS to its 
receptor TLR4 (13, 30) and inhibit the inflammatory response (30). Further, in animal 
models intraperitoneal injection (IP) injection of CTRP3 (0.4ug/g body weight) 
significantly reduced LPS-induced (IP) inflammatory response (65). Although 
intravenous administration of CTRP3 was unable to prevent LPS-induced inflammation, 
this is thought to be a dose related limitation and future studies are ongoing to 
determine the clinically relevant levels of CTRP3 administration needed to inhibit a 
systematic immune response. Further, CTRP-3 potently inhibited LPS-induced IL-6 in 
monocytes isolated from healthy subjects but not in monocytes derived from a subject 
with T2D (31, 70). Similarly, the anti-inflammatory effects of CTRP3 have also been 
observed in isolated primary human colonic fibroblasts (21). Combined, these data 
show promise for the use of CTRP3 and CTRP3-mediated pathways as a potential anti-
inflammatory mediator. However, neither chronic CTRP3 deficiency nor overexpression 
altered the inflammatory response to a sublethal challenge to LPS (48), indicating that 
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CTRP3 levels need to be regulated transiently to demonstrate an anti-inflammatory 
effect. Regardless, the potential use of CTRP3 as an inhibitor of inflammation needs to 
be examined in more detail. 
Growth, Reproduction, and Tumorigenesis 
CTRP3 has been linked to normal and pathogenic cellular proliferation, growth 
and development. CTRP3 has been consistently shown to stimulate the proliferation of 
chondrogenic precursors, chondrocytes, and osteocytes, in vitro, through activation of 
ERK1/2 and PI3K pathways (1, 3, 27, 44, 82). During early development CTRP3 is 
detected in developing chondrocytes (43) and cartilage (44) which has led to the 
hypothesis that CTRP3 is essential for normal cartilage and bone development. In 
support of this CTRP3 is appears to be essential for proper mandible formation through 
perichondrium maintenance and new cartilage formation (82). However, the role of 
CTRP in development may be dispensatory as CTRP3-knockout animals do not 
demonstrate a growth phenotype indicating a possible compensatory mechanism during 
development. However, CTRP3-knockout mice do exhibit increased susceptibility to 
collagen-induced arthritis, indicating CTRP3 may be important for the maintenance and 
repair of cartilage tissue (46). However, elevated CTRP3 may also be detrimental as 
CTRP3 is highly secreted from and increases growth rates of osteosarcoma and 
chondroblastoma tumor cell lines indicating that CTRP3 may be linked to these types of 
cancers (54). However, no cancers have been reported in CTRP3 transgenic 
overexpressing mice, although this has not been specifically examined. Lastly, CTRP3 
is specifically expressed in the testosterone producing interstitial Leydig cells and 
treatment of TM3 mouse Leydig cells with CTRP3 increased testosterone production 
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(47). Although these findings may shed some light on the discrepancy between male 
and female in circulating CTRP3 levels, the overall clinical significance has yet to be 
explored. 
SUMMARY AND CONCLUSION 
Adipose tissue secretes numerous adipokines that contribute to a wide array of 
biological processes. CTRP3, is a novel and unique member of the adipokine 
superfamily which appears to have unique roles in a variety of tissue: hepatic lipid 
metabolism, cardiovascular response to ischemia, and increases chondrocyte 
proliferation and differentiation. CTRP3 can function in an autocrine, paracrine, and 
endocrine manner and there are many aspects of CTRP3’s regulation and function that 
have yet to be explored. In addition, CTRP3 has been consistently linked to activation of 
the PKA signaling pathway, regardless of the tissue/treatment paradigm examined (37, 
47, 80). This review should serve as a basis for the design of future experimental 
studies specifically examining: (i) the regulation of CTRP3 in response to food intake or 
exercise, (ii) associations between circulating CTRP3 levels, including the two different 
splice variants (CTRP3A and CTRP3B), and hepatic steatosis or osteoscarcoma in 
clinical population, and (iii) the associations between the different CTRP3 isoforms 
(CTRP3A and CTRP3B) and multimeric structures in clinical populations, (iv) the 
potential use of CTRP3 as an inhibitor of inflammation, and (v) whether the putative 
receptors, LAMP-1 and LIMPII are directly responsible for the intracellular effects 
of CTRP3 or at as co-receptors for a yet unidentified protein. Finally, the gender-specific 
regulation of CTRP3 needs to be explored in more detail (splice variants and multimeric 
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structures) especially in regards to the association between CTRP3 and human 
diseases such as non-alcoholic fatty liver disease, T2D, and metabolic syndrome. 
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ABSTRACT 
C1q/TNF Related Protein 3 (CTRP3) is a member of a family of secreted proteins that 
exert a multitude of biological effects. Our initial work identified CTRP3’s promise as an 
effective treatment for Nonalcoholic fatty liver disease (NAFLD). Specifically, we 
demonstrated that mice fed a high fat diet failed to develop NAFLD when treated with 
CTRP3. The purpose of this current project is to identify putative receptors which 
mediate the hepatic actions of CTRP3. We used Ligand-receptor glycocapture 
technology with TriCEPS™-based ligand-receptor capture (LRC-TriCEPS; Dualsystems 
Biotech AG). The LRC-TriCEPS experiment with CTRP3-FLAG protein as ligand and 
insulin as a control ligand was performed on the H4IIE rat hepatoma cell line. Initial 
analysis demonstrated efficient coupling of TriCEPS to CTRP3. Further, flow cytometry 
analysis (FACS) demonstrated successful oxidation and crosslinking of CTRP3-
TriCEPS and Insulin-TriCEPS complexes to cell surface glycans. Demonstrating the 
utility of TriCEPS under these conditions, the insulin receptor was identified in the 
control dataset. In the CTRP3 treated cells a total enrichment of 261 peptides was 
observed. From these experiments 5 putative receptors for CTRP3 were identified with 
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two reaching statistical significance: Lysosomal-associated membrane protein 1 (LAMP-
1) and Lysosome membrane protein 2 (LIMP II). Follow-up Co-immunoprecipitation 
analysis confirmed the association between LAMP1 and CTRP3 and further testing 
using a polyclonal antibody to block potential binding sites of LAMP1 prevented CTRP3 
binding to the cells. The LRC-TriCEPS methodology was successful in identifying 
potential novel receptors for CTRP3. The identification of the receptors for CTRP3 is an 
important prerequisites for the development of small molecule drug candidates, of which 
none currently exist, for the treatment NAFLD. 
INTRODUCTION 
Since the discovery of leptin by Zhang et al. (1) many secreted bioactive 
molecules have been identified which originate from adipose tissue. Thus far, over 260 
unique adipose tissue derived secreted proteins/peptides have been identified, 
collectively termed adipokines (2-5). Efforts to identify such metabolic regulators have 
led to the discovery of a family of secreted proteins, designated as C1q/TNF-Related 
Proteins, with 15 unique proteins currently identified (CTRP1-15) (6-14). C1q family 
proteins are characterized by a distinctive ‘globular domain’ of about 140 amino acids 
(the gC1q domain) (14). The CTRP proteins, adiponectin, TNF-alpha, as well as other 
proteins with the C1q domain are collectively referred to as the C1q/TNF superfamily 
(14-18). Proteins within the C1q/TNF superfamily share some structural similarities, but 
may have apposing functions (18). To date, many unique functions have been identified 
for the CTRP proteins encompassing regulatory roles in metabolism, inflammation and 
cell proliferation (6, 9, 15-29). Of these proteins our lab has identified a liver specific role 
for CTRP3 in preventing Nonalcoholic fatty liver disease (NAFLD) (29). 
  78 
Adiponectin, the most widely studied member of the C1q/TNF superfamily, increases 
lipid oxidation in liver and skeletal muscle (16, 30-32). Unlike adiponectin or other C1q 
TNF related proteins, we observed no direct effect of CTRP3 on skeletal muscle in 
vitro or in vivo (9, 29). This implies that CTRP3 works through a novel receptor, as the 
three identified receptors for adiponectin are all present in skeletal muscle (33-35). In 
further support of this hypothesis both CTRP3 and adiponectin decrease hepatic TAG 
accumulation, however adiponectin reduces hepatic triglyceride levels largely through 
activation of AMP-activated protein kinase (AMPK) pathways (32), whereas CTRP3 did 
not affect AMPK phosphorylation status (9, 29). The finding of divergent downstream 
signaling pathways also argues that CTRP3 has a receptor distinct from adiponectin. 
Combined, these data indicate that CTRP3 is a distinct member of the C1q/TNF 
superfamily and functions through a unique receptor in liver. The receptor and the 
mechanism(s) responsible for the CTRP3-induced reduction in hepatic TAG 
accumulation remain unexplored. 
LRC-TriCEPS™ is promising, novel technology recently described in Nature 
Protocols and Nature Biotechnology (36, 37). First published by the lab of Bernd 
Wollscheid, TriCEPS™ is a chemoproteomic reagent coupled to a ligand of interest 
(CTRP3) that acts to covalently link the ligand to the cell-based receptor (36). This 
linkage protects the ligand-receptor conjugate from the subsequent digestion steps and 
peptide level purification via the biotin tag on the TriCEPS™ molecule. The TriCEPS™ 
and the ligand are subsequently released through specific enzymatic cleavage and the 
receptor peptides are collected and analyzed by Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The LRC-TriCEPS™ technique has been validated through 
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successful detection of known receptors, however, using this technology to identify 
receptors for novel proteins is still in its infancy (36, 37). 
The purpose of this study was to determine if we could successful use the LRC-
TriCEPS™ to identify novel potential receptors which mediate the hepatic effects of 
CTRP3. In brief, we were able to identify five potential novel receptors using the LRC-
TriCEPS™ technique. 
EXPERIMENTAL PROCEDURES 
Cell culture. HEK-293T cells (Thermo fisher, GripTite 293 MSR Cell Line Cat # 
R79507) were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) with 4.5 
g/L glucose without L-glutamine and sodium pyruvate (Corning, Cat# 15-017) 
supplemented with 5% (v/v) fetal bovine serum (HyCloneTM, Cat# SH30088.03) and 
with antibiotic/antimycotic Solution (Corning, Cat# 30-004-CI). HEK-293T cells were 
used for transfection and protein purification protocols. H4IIE cells (H-4-II-E rat 
hepatoma cells, ATCC® cat# CRL-1548™, RRID:CVCL_0284) were cultured in DMEM 
containing 1 g/L glucose, L-glutamine, and sodium pyruvate (Corning Cat# 10-014) 
supplemented with 10% (v/v) fetal bovine serum (HyCloneTM, cat# SH30088.03) and 
with antibiotic/antimycotic Solution (Corning, Cat# 30-004-CI). H4IIE rat hepatoma cells 
are a well-established in vitro model of hepatocytes, useful for metabolic research as 
this cell line mirrors the liver-like, insulin regulated glucose and lipid metabolism found in 
the liver (38-40). Further, the CTRP3 amino acid sequence is highly conserved 
throughout vertebrate evolution with only 4 amino acids differing between the mouse 
and rat orthologs and a 95% homogeneity between mouse and human (6, 9). Therefore, 
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we expect that the receptor and metabolic effects of CTRP3 established in H4IIE cell 
line in vitro will provide insight to the actions of CTRP3 in vivo.  
Protein purification. C-terminal FLAG-Tagged mouse CTRP3 and CTRP1 were 
produced as described previously (9, 41). Briefly, transient transfections were 
performed on HEK-293T cells using calcium phosphate according to standard protocols 
(42). At 48 h after transfection, cells were washed and then cultured in serum-free Opti-
MEM I medium (Invitrogen, Cat# 51985034) supplemented with vitamin C (0.1 mg/ml; 
Fisher Scientific Company, Cat# FLBP351). Supernatants were collected three times, 
every 48 h, pooled and purified using an anti-FLAG affinity gel according to the 
manufacturer's protocol (Biotool.com, Cat# B23101), and eluted with 150 μg/ml FLAG 
peptide (Sigma, Cat# F4799). Dialysis was performed on purified proteins with 20 mM 
Hepes buffer (pH 8.0) containing 135 mM NaCl in a 10 kDa cut-off Slide-A-Lyzer 
dialysis cassette (Thermo Fisher Scientific, Cat# 88252). 
Immunofluorescence. For visualization H4IIE hepatocytes were grown to 
confluence on Millicell EZ SLIDE (Millipore Cat# PEZGS0816) in standard growth 
medium. The cells treated with recombinant FLAG tagged CTRP3, CTRP1, or vehicle 
for 1 hr. Afterwards the cells were washed in phosphate buffered saline (PBS; 137 mM 
NaCl, 10 mM Phosphate, 2.7 mM KCl, ph 7.2) fixed in 4% formaldehyde diluted in PBS 
for 10 minutes at 37°C, washed with PBS, and then blocked in 5% Normal goat serum 
(diluted in PBS). The cells were then incubated with rabbit anti-FLAG (Cell Signaling 
Technology Cat# 14793; RRID: AB_2572291) followed by fluorochrome-conjugated 
secondary antibody (Cell Signaling Technology Cat# 4412 RRID: AB_1904025). Cells 
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were then mounted with an anti-fade mounting medium with DAPI (DAPI Fluoromount-
G®; SouthernBiotech Cat# 0100-20), and immunofluorescence was visualized [Zeiss 
Observer.Z1].  
Fatty acid oxidation. H4IIE hepatocytes were allowed to adhere to 24-well 
culture plates XF24 cell culture microplate (Seahorse Bioscience, Cat# 100777-004) 
after seeding for 2 days, according to standard protocols (Seahorse Bioscience). Cells 
were pre-incubated with 5 µg/ml CTRP3 or vehicle for 1 H then transferred into XF 
assay medium (Seahorse Bioscience, Cat# 100965-000) supplemented with 0.5mM 
sodium pyruvate and 5mM glucose before being placed into the XF24 Extracellular Flux 
Analyzer (Seahorse Bioscience XF24). The dosage of recombinant CTRP3 was 
selected based on our previous experimental observations (9), and is well within the 
common dosages reported within the literature of 2-30 µg/ml (9, 29, 43, 44).  Sensor 
cartridge of XF24 extracellular flux assay kit (Seahorse Bioscience, Cat# 100850-001) is 
hydrated by loading 1ml XF calibrant (Seahorse Bioscience, Cat# 100840-000) into 
each well in utility plate and incubating at 37°C overnight in a non-CO2 incubator. 200 
uM palmitate conjugated to bovine serum albumin (BSA) or fatty acid free BSA (served 
as a vehicle control) was added in XF24 cell culture microplate at time-points indicated. 
A 1 mM working stock of palmitate (Sigma Cat# P5585) conjugated to 0.17 mM fatty 
acid free BSA (Sigma Cat# A8806) was prepared according to established protocols 
(Seahorse Bioscience). Briefly, 50 ml of a BSA solution (0.34 mM BSA, 150 mM NaCl, 
pH 7.4) was heated to 37°C and 40 ml of a palmitate solution (2.98 mM palmitate, 150 
mM NaCL), heated to 70°C, and was added in 5 mL increments.  The combined 
solution was incubated at 37°C for 1 H under constant agitation, afterwards the pH was 
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adjusted to 7.4 and the final volume was adjusted to 100 mL with 150 mM NaCl. 
Aliquots were stored until use at -20°C in glass vials. 
Flow Cytometry. H4IIE hepatocytes were grown to confluence in 6-well plates 
(Corning Costar® Cat# 3516) and then treated with/without recombinant CTRP3-FLAG 
for indicated times. The cells were then collected in PBS, fixed in 4% formaldehyde, and 
then incubated with rabbit anti-FLAG antibody (Cell Signaling Technology, Cat# 14793; 
RRID: AB_2572291) followed by fluorochrome-conjugated secondary antibody (Cell 
Signaling Technology, Cat# 4412; RRID:AB_1904025). Next cells were suspended in 
buffer (0.5% Bovine Serum Albumin in PBS) and analyzed for mean fluorescent 
intensity (MFI) by using a FACScalibur flow cytometer with (CellQuest software, BD 
Biosciences). Except for the quality control step for LRC-TriCEPS (see below), all FACS 
experiments were performed three separate times in triplicate for each experiment. For 
blocking experiments cells were co-incubated with polyclonal Lysosomal-associated 
membrane protein 1 (LAMP-1) antibody (Santa Cruz Biotechnology Cat# sc-8098, 
RRID:AB_2134494) 
TriCEPS™-based ligand-receptor capture (LRC-TriCEPS). In conjunction with 
Dualsystems Biotech AG, TriCEPS™-based ligand-receptor capture (LRC-TriCEPS; 
Dualsystems Biotech, cat# P05201) was utilized to identify the putative receptor for 
CTRP3 according to manufacturers directions. Briefly, 300 µg recombinant CTRP3-
FLAG protein or Insulin (control ligand) was dissolved in 150 µl HEPES buffer (25 mM, 
pH 8.2) and 1.5 μl of the TriCEPS™ reagent was added to each sample and incubated 
for 2 H at 20°C under constant gentle agitation. After incubation 1µl of each sample was 
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removed to complete a Dot blot experiment as a quality control to test for efficient 
TriCEPS™ coupling to the ligands (data not shown). Three separate 50 mL tubes each 
containing 2x108 H4IIE Hepatocytes in PBS (pH 6.5) were washed and cooled to 4°C, 
all subsequent steps were performed at 4°C.  200 μl was collected from each tube and 
labeled as non-oxidized cells.  Next, to mildly oxidize the cell surface proteins 1.5 mM 
NaIO4 was added to each tube and cells were incubated at 4°C in the dark for 15 min 
under gentle rotation.  The cells were then washed twice at 300 x g for 5 min and then 
resuspended in 20 ml PBS (pH 6.5). An aliquot of ~80 μl was collected from each tube 
and labeled as oxidized cells.  The cells were then evenly divided into 6 separate tubes 
and 50 µl of either TriCEPS™-coupled insulin or TriCEPS™-coupled CTRP3 was added 
to each tube and incubated for 90 min at 4°C under constant gentle agitation. An aliquot 
of ~80 µl was collected from each tube and the collected samples (non-oxidized cells, 
oxidized cells, insulin cells and CTRP3-FLAG cells) were analyzed by FACS to test for 
the crosslinking efficiency of the TriCEPS™-ligand complexes to the cell surface 
glycans using fluorochrome conjugated streptavidin (Thermo Fisher Scientific Inc. 
eBioscience Cat# 11-4317).  After completion of the coupling reaction, the cells were 
collected and the cell pellet was sent to Dualsystems for LC-MS/MS analysis.  
LC-MS/MS analysis. The samples were analyzed on a Thermo LTQ Orbitrap XL 
spectrometer fitted with an electrospray ion source. The samples were measured in 
data dependent acquisition mode in a 60 min gradient using a 10cm C18. The six 
individual samples in the dataset were analyzed with a statistical ANOVA model. This 
model assumes that the measurement error follows Gaussian distribution and views 
individual features as replicates of a protein's abundance and explicitly accounts for this 
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redundancy. It tests each protein for differential abundance in all pairwise comparisons 
of ligand and control samples and reports the p-values. Next, p-values are adjusted for 
multiple comparisons to control the experiment-wide false discovery rate (FDR). The 
adjusted p-value obtained for every protein is plotted against the magnitude of the fold 
enrichment between the two experimental conditions. Proteins are considered 
significant if FC>2 and adj. p-value<0.05. 
Co-Immnunoprecipitation (Co-IP) and Immunoblot Analysis. H4IIE hepatocytes 
were grown to confluence in 6-well plates (Corning Costar® Cat# 3516) and then 
treated overnight with/without recombinant CTRP3-FLAG overnight.  The cells were 
then washed with PBS and collected in Non-denaturing lysis buffer (20 mM Tris HCl pH 
8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA).  Cells were incubated 
with constant agitation for 30 minutes at 37°C and then centrifuged at 10,000xg at 4°C 
for 10 minutes and the supernatant was collected and protein concentration was 
determined via Bradford assay (Pierce Coomassie Plus Cat# 23238). Equal amounts of 
protein were diluted to 500 µl final volume and used for immunoprecipitation according 
to manufactures directions (Bimake, Anti-DYKDDDDK(Flag) Affinity Gel Cat# B23101). 
Total protein homogenate or immunoprecipitate were loaded and separated on a 12% 
Mini-Protean® TGXTM gel (Bio-Rad, Cat#456-1046) and transferred to nitrocellulose 
membranes (0.45 μm, Bio-Rad Cat#1620115). Membranes were blocked in 2% non-fat 
milk and probed with primary antibodies overnight at 4°C (Anti-LAMP1, Abcam Cat# 
ab24170, RRID:AB_775978; or Anti-LIMPII, Abcam Cat# ab176317, RRID: 
AB_2620169) followed horseradish peroxidase (HRP)-conjugated goat anti-rabbit 
secondary antibody (Thermo Fisher Scientific Cat# 31460, RRID:AB_228341). 
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Membranes were incubated with HRP Substrate (Millipore Immobilon Cat# 
WBKLS0100) and chemiluminescence was then visualized with FuorChem® M imager 
(ProteinSimple). Precision Plus Protein™ Dual Color Standards molecular weight 
markers were used in all immunoblot analysis (BioRad Cat#161-0374). 
Statistical Analysis. For analysis of flow cytometry and fatty acid oxidation, data 
from each experiment were normalized to the control and the combined data from the 
three independent replicates was combined and analyzed with a one-way ANOVA (flow 
cytometry) or repeated measure ANOVA (fatty acid oxidation) followed by Tukey's 
multiple comparisons test Post hoc analysis. Statistics analysis were completed by 
Graphpad Prizm version 6. 
RESULTS 
CTRP3 binds and has a physiological effect on hepatoma cells 
Immunohistochemical analysis was used to demonstrate that recombinant 
CTRP3, but not CTRP1 binds to H4IIE hepatocytes in vitro (Figure 4.1). Confirmatory 
experiments using flow cytometry demonstrated a 200% increase in mean fluorescent 
intensity (MFI) when cells were treated with recombinant FLAG tagged CTRP3 and 
probed with anti-FLAG antibodies, compared with vehicle, and fluorochrome-conjugated 
secondary antibody alone treatments (Figure 4.2C). Interestingly, only a subset (~20%) 
of H4IIE cells stained positive for CTRP3 binding. This may indicate that CTRP3 
receptor surface expression is transient. For instance, it may be yoked to the cell cycle 
or some other parameter of cellular circumstance. 
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Figure 4.1:  CTRP3 Binds to Hepatocytes In Vitro. H4IIE hepatocytes were plated on Millicell EZ 
SLIDE (Millipore) and allowed to adhere for 48 H in standard growth medium. The cells were 
treated with recombinant FLAG tagged CTRP3, CTRP1, or vehicle the cells were then 
incubated with rabbit anti-FLAG primary antibody followed by fluorochrome-conjugated 
secondary antibody. Cells were then mounted with an anti-fade mounting medium with DAPI, 
and immunofluorescence was visualized. 
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Figure 4.2:  CTRP3 Binds to Hepatocytes in Vitro. H4IIE hepatocytes were grown in standard 
media and then treated for 1 H ± CTRP3-FLAG (5 µg/ml). The cells were then washed and 
collected in PBS, fixed in 4% formaldehyde, and then incubated with rabbit anti-FLAG antibody 
followed by fluorochrome-conjugated secondary antibody and analyzed for mean fluorescent 
intensity (MFI) by flow cytometry.  Representative image (20% of points shown) of raw flow data 
from vehicle treated (A) or CTRP3-FLAG treated (B).  C, the MFI ± CTRP3 normalized to 
vehicle for each independent replicate. D, Percent of the cells that were positive for each 
experiment.  Data for figures C & D are from 3 independent replicates performed on different 
days with separate lots of recombinant CTRP3-FLAG protein with each replicate performed in 
triplicate and reported as mean ± SD. * P < vs. 0.0001 vehicle. 
The next series of experiments examined the effects of CTRP3 on hepatocyte 
oxygen consumption to determine if the binding of CTRP3 to the hepatocytes resulted in 
a physiological effect. Pre-treatment with recombinant CTRP3 (5 μg/ml) had no effect 
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on lipid oxidation in hepatocytes under standard conditions. However, in the presence of 
an excess of free fatty acids (200 μM palmitate) there was 24% increase in total oxygen 
consumption in the CTRP3 pre-treated cells, indicating greater FFA utilization (Figure 
4.3). 
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 Figure 4.3:  CTRP3 Increases Oxygen Consumption. Cells were pre-incubated with 5 µg/ml 
recombinant CTRP3 or vehicle for 1 H before being placed into the XFe24 Extracellular Flux 
Analyzer (Seahorse Bioscience) and oxygen consumption rate (OCR) was determined. OCR was 
measured in the absence (A) or after the addition of 200 µM palmitate (B) added at 15 minutes 
(vertical line). C, Area under the curve was calculated (mean OCR value at each interval*time) 
for each treatment. Data represents the mean ± SD. Data is pooled from 3 independent 
experiments each performed in triplicate, *P < 0.05 vs. vehicle + palmitate. 	
TriCEPS™-based ligand-receptor capture (LRC-TriCEPS) 
An experiment with CTRP3-FLAG protein as a ligand and insulin as a control 
ligand was performed on the H4IIE rat hepatoma cell line. Control experiments to 
assess the technical quality were performed in parallel. Briefly, flow cytometry showed 
successful oxidation and crosslinking of CTRP3-TriCEPS and Insulin-Triceps to the cell 
surface glycans (Figure 4.4A). LC-MS/MS analysis showed a total enrichment of 
glycopeptides of 11% (261 peptides). Under these conditions, INSR (insulin receptor) 
could be identified and quantified in the control dataset. From these experiments 5 
putative receptors for CTRP3 were identified with two reaching statistical significance: 
Lysosomal-associated membrane protein 1 (LAMP-1) and Lysosome membrane protein 
2 (LIMP II) (Table 4.1 and Figure 4.4B) As LAMP1 was the promising candidate further 
experiments were carried out focusing on LAMP1. 
Table 4.1:  Table 8TriCEPS™-Based Ligand-Receptor Capture (LRC-TriCEPS) 
TriCEPS™-Based Ligand-Receptor Capture (LRC-TriCEPS) 
 
Uniprot 
identifier  
Protein  Number of 
peptides  
log2FC  adj.pvalue  
P14562  LAMP1  4  1.00  5.79E-05  
P27615  LIMPII 2  1.06  0.035  
P16391  HA12  3  0.53  0.046  
D3ZQ57  D3ZQ57  2  0.50  0.046  
Q66HD0  ENPL  2  1.13  0.072  
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Figure 4.4:  H4IIE Rat Hepatoma Cells Were Treated With TriCEPs Conjugated to Insulin or 
CTRP3. A, The binding of ligands to cell surface receptors was detected by Steptavidin FITC 
(The TriCEPS™ reagent contains biotin) and analyzed for mean fluorescent intensity (MFI). 
Representative image (20% of points shown) of raw flow data from vehicle treated.  B, The 
samples were analyzed by Mass spectrometry (Dualsystems Biotech, AG) and the adjusted p-
value (ANOVA, adjusted for multiple comparisons) for the differential abundance of each protein 
was plotted against the magnitude of the fold enrichment between insulin and CTRP3 samples.  
Proteins are considered significant if fold change >2 and P<0.05.  Two proteins (LAMP1 and 
LIMPII) were statistically significant.  
LAMP1 antibody prevents CTRP3 binding 
To follow up the LRC-TriCEPS experiment we repeated the FACS experiments 
with the addition of a polyclonal antibody to LAMP1 in an attempt to disrupt the binding 
of CTRP3. The co-incubation of H4IIE cells with recombinant CTRP3 and anti-LAMP1 
polyclonal antibody was found to significantly attenuate the binding of CTRP3 to H4IIE 
cells (Figure 4.5E and F). 
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Figure 4.5:  Blocking LAMP1 Suppresses CTRP3 Binding. H4IIE hepatocytes were grown to 
confluence in standard media and then treated for overnight ± CTRP3-FLAG (2.5 µg/well) and ± 
polyclonal LAMP1 antibody (10 µg/well, to block potential CTRP3 binding sites). The cells were 
then washed and collected in PBS, fixed in 4% formaldehyde, and then incubated with rabbit 
anti-FLAG antibody followed by fluorochrome-conjugated secondary antibody and analyzed for 
mean fluorescent intensity (MFI) by flow cytometry.  A-D, Representative flow data from H4IIE 
hepatocytes. A MFI >100 was taken as positive and is indicated in the flow plots with a gray bar.   
A, pooled cells with no primary antibody (isotype or negative control). B, cell incubated with 
vehicle, C, recombinant CTRP3-FLAG protein, or D, co-incubated with recombinant CTRP3-
FLAG protein plus poly-clonal anti-LAMP1. E, Percent of the cells that were positive from each 
experiment.  F, the MFI ± CTRP3 normalized to vehicle for each independent replicate. Data for 
figures E & F are from 3 independent replicates performed on different days with separate lots 
of recombinant CTRP3-FLAG protein with each independent replicate performed in triplicate 
and reported as mean ± SD. * P < 0.001 vs. vehicle; ** P < 0.001 vs. CTRP3+LAMP1. 
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CTRP3 Co-IP 
We found that treatment with CTRP3 did not affect LAMP1 protein 
concentration in total lysate (Figure 4.6C). To determine whether CTRP3 interacted with 
LAMP1 protein a Co-IP assay was performed. Immunoblot analysis was able to 
successfully identify LAMP1 in the CTRP3 Co-precipitate and not in the FLAG peptide 
or buffer only treated cells, further supporting the hypothesis that CTRP3 and LAMP1 
associate in vivo (Figure 4.6D). 
 
Figure 4.6:  Co-Immnunoprecipitation (Co-IP) and Immunoblot Analysis. H4IIE cells were 
treated overnight with vehicle, FLAG peptide, or recombinant FLAG tagged CTRP3 (rCTRP3). 
Total protein homogenate (A & C) or immunoprecipitate (B & D) were separated by SDS-page 
gel and transferred to nitrocellulose membrane. A & B, after immunoblot total protein was 
visualized by brief incubation with Ponceau S staining solution (5% acetic acid & 0.1% Ponceau 
S). C, LAMP1 in total protein homogenate was similar between treatments. D, Co-IP results 
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showing LAMP1 binds to CTRP3. Samples were immunoprecipated with anti-FLAG Affinity Gel 
followed by immunoblotting with antibodies against LAMP1.   
DISCUSSION 
Summary of Findings 
We successful showed using two different techniques that recombinant purified 
mammalian-expressed CTRP3 protein binds to the H4IIE hepatoma cells. Further, using 
real-time oxygen consumption data we demonstrate that pre-conditioning cells with 
CTRP3 increased oxygen consumption rates. Because electrons produced by free fatty 
acid (FFA) beta-oxidation enter the electron transport chain at the level of complex 2 
while those derived from glucose enter at complex 1, a switch from glucose to FFA 
utilization is accompanied by higher oxygen consumption rates (45, 46). Theoretically, 
the switch from glucose to FFA should cause ~30% increase in OCR (46, 47), if ATP 
turnover remains unchanged. The ~24% increase observed in oxygen consumption 
supports previous findings that CTRP3 increases FFA oxidation in hepatocytes (29). 
Lastly, the LRC-TriCEPS experiments successfully identified and quantified statistically 
two proteins as targets for CTRP3: LAMP1 and LIMPII. Additionally, 3 other potential 
candidates were identified, and although there were not statistically quantified they were 
reported as putative receptors (Table 4.1). Follow-up experiments with an anti-LAMP1 
polyclonal antibody partially attenuated the binding of CTRP3 to the cells and Co-IP 
experiments further confirmed that LAMP1 associates with CTRP3. 
Study Limitations 
Although we were successfully able to identify potential proteins which act as 
the receptor to mediate the effects of CTRP3 there are some study limitations that need 
to be addressed. This study used an immortalized cell line as a model for hepatocytes. 
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H4IIE cells were chosen because they are a commonly used liver cell culture line that 
maintains characteristics of intact liver cells and we have shown previously that CTRP3 
had a physiological response in these cells (i.e. reduced neutral lipid accumulation 
(29)). Further, the LRC-TriCEPS protocol requires isolated cells and isolation of 
hepatocytes from intact liver requires enzymatic dissociation which by definition disrupts 
cell surface proteins. Future visualization and co-localization studies using intact liver 
will need to be performed. Additionally, binding and lipid oxidation experiments with 
primary hepatocytes also need to be performed. Lastly, the identification of putative 
receptors that are not exclusively expressed in hepatocytes still leaves open the 
possibility that the liver-specific in vivo effects of CTRP3 (29) are mediated through 
indirect mechanisms and not necessarily through direct actions of CTRP3 on 
hepatocytes. 
Hepatic function of CTRP3 
Previous work has shown that the novel adipokine CTRP3 has a potent 
biological effect on the liver (9, 29). Briefly, both transgenic overexpression of CTRP3 
and daily administration of recombinant CTRP3 reduced diet-induced hepatic 
triglyceride accumulation (29). Further, acute injections of recombinant CTRP3 
significantly lowered hepatic gluconeogenesis up to 8 H post injection (9). However, the 
mechanism by which CTRP3 attenuates hepatic triglyceride levels or gluconeogenesis 
is unknown. Due to the similarity of CTRP3 and other members of the CTRP family to 
adiponectin it has been suggested that the actions of all members of the CTRP family 
are mediated through the adiponectin receptors: T-cadherin, and adiponectin receptors 
1 and 2 (35, 48). However, our previous work suggests that CTRP3 works through a 
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novel mechanism, as unlike adiponectin, CTRP3 did not increase hepatic AMPK 
phosphorylation (9, 29, 32). Moreover, we observed no effect of CTRP3 treatment in 
skeletal muscle, which has all three of the known receptors for adiponectin (9, 33, 34). 
Lastly, we have shown that CTRP3 but not CTRP1 binds to hepatocytes in vitro (Figure 
4.2), which supports our hypothesis that CTRP3 is a distinctive member of the C1q/TNF 
superfamily and functions through a unique receptor. 
Functions of LAMP1 and LIMPII 
LAMP1 [Uniprot identifier P14562 (Figure 4.7)] is also known as 120 kDa 
lysosomal membrane glycoprotein (LGP-120) and CD107 antigen-like family member A 
(CD107a). LAMP1 was initially characterized as a type 1 integral lysosomal membrane 
glycoprotein that is found in a wide variety of tissues (including the liver) and is 
commonly used as a lysosomal marker (49, 50). However more recently it has been 
reported that LAMP1 also shuttles to the plasma membrane, indicating that it could act 
as a cell surface receptor (51, 53). Further, ~5% of the total LAMP1 protein is located on 
the plasma membrane due to lysosomal fusion (51, 54). The transient nature of LAMP1 
plasma membrane associate could explain why, in a theoretically homologous cell 
culture population, only about 15–20% of the cells appeared to be positive for CTRP3 
binding (Figure 4.1 and 4.2). Regardless, we were able to show that pretreatment with 
CTRP3 was sufficient to induce a significant increase in oxygen consumption. Although 
LAMP1, in addition to LAMP2, account for ~50% of lysosomal membrane proteins (49) 
the exact function for LAMP1 remains elusive, as LAMP1 knockout mice do not appear 
to have any functional or structural abnormality (49, 52). Currently, it is believed that 
LAMP1 is partly responsible for maintaining lysosomal integrity and function (49), and 
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plasma membrane expression of LAMP1 may play a role in tumor cell differentiation 
and metastasis (49). The potential role of LAMP1 in mediating hepatic lipid oxidation 
has not been explored. 
A 
 
B 
 
Figure 4.7:  Protter Visualization of Identified Peptide. The identified peptides of LAMP1 (A) and 
LIMP II (B) are visualized with Protter [62].  Identified peptide sequences are signified by blue 
circles. 
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Lysosome membrane protein 2 (LIMPII, Uniprot identifier P27615) is also 
known as Scavenger receptor class B member 2 (SCRB2), 85 kDa lysosomal 
membrane sialoglycoprotein (LGP85), and as CD36 antigen-like 2. LIMPII was first 
discovered in a rat liver lysosomal fraction (55) and accounts for ~4% of all lysomal 
proteins (56). Although the presence of LIMPII on the plasma membrane of hepatocytes 
has not been examined, LIMPII has been shown to be essential in the cell-to-cell 
adhesion of the plasma membrane of cardiac myocytes (intercalated discs) (57). 
Although the exact function in metabolism for LIMPII is unknown the closely related 
protein Scavenger receptor class B member 3 (SCARB3, also known asCD36/FAT) has 
been implicated in hepatic insulin resistance (58, 59) and immunity (60), both functions 
implicated with CTRP3. Like SCARB3, LIMPII has been shown to bind to the adhesive 
glycoprotein thrombospondin-1 (56), which may help mediate cell-to-cell interactions. 
LIMPII is primarily expressed in the liver, placenta, adrenal cortex and adrenal gland 
(50) and has already been implicated as an internal receptor responsible for shuttling 
the enzyme glucocerebrosidase to the lysosome. Glucocerebrosidase metabolizes the 
sphingolipid glucocerebroside, and when deficient results in Gaucher disease (or the 
excessive accumulation of the lipid molecule glucocerebroside in cells (i.e. hepatocytes) 
(61). 
Although lacking known cellular signaling functions, both LAMP1 and LIMPII are 
expressed in hepatic cells, where they are potentially positioned to interact with CTRP3. 
Further, both of these proteins can be found on the cell surface however, they may act 
as a co-receptor for an as-yet-unidentified signaling receptor through which CTRP3 
transmits metabolic signals. 
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SUMMARY AND CONCLUSION 
Previous work has shown that the novel adipokine CTRP3 has a potent 
biological effect on the liver (9, 29). However, the mechanism by which CTRP3 
attenuates hepatic triglyceride levels is unknown. The purpose of this study was to 
determine if we could successfully use the relatively new methodological approach, 
LRC-TriCEPS™ method, to identify potential receptors, which mediate the biological 
effects of CTRP3. We have successfully identified two potential novel receptors using 
the LRC-TriCEPS™ technique: LAMP1 and LIMPII. Although, the intracellular signaling 
mechanism remains unknown the identification of the receptors for CTRP3 and other 
members of this family is an important prerequisite of the development of small 
molecule drug candidates that work through CTRP3 receptors to exert effects beneficial 
to human health. 
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CHAPTER 5 
 
SUMMARY & FUTURE DIRECTIONS 
 
HIF-1α 
The studies described in the proceeding chapters provided insight into the 
cellular mechanisms by which HIF-1α and CTRP3 mediate metabolic changes to 
combat stress. HIF-1α remodels metabolism to confer ischemic cardioprotection. In the 
present studies, enhanced glycolytic flux in HIF-1α hearts ex vivo was indicated by 
significantly higher 13C-labeled lactic acid accumulation as ischemia progressed (0 to 30 
mins). Additionally, phosphorylation of glycogen synthase was significantly upregulated 
by HIF-1α. Because phosphorylation deactivates GS, this favors glycogenolysis in the 
ischemic heart. These findings are consistent with our previous data that lactate 
released into the perfusate was significantly elevated following ischemia of HIF-1α heart 
at 30 mins (J. Wu et al. 2013). In spite of the increase of glycolytic flux, paradoxically, 
we found that 13C-labeled glycogen (glucose reserves) levels were maintained at pre-
ischemic levels in HIF-1α hearts for up to 30 mins of ischemia, whereas glycogen levels 
were depleted after 5 mins of ischemia in WT hearts.  In addition, the rate of 13C-
Glucose incorporation into glycogen is maintained at pre-ischemic levels in HIF-1α 
hearts for up to 30 mins of ischemia while becoming undetectable in WT hearts. 
Combined these findings suggest that HIF-1α is responsible for an unexpected source 
of glucose that contributes to the glucose:glycogen turnover during no-flow ischemia in 
heart. Further, our experiments demonstrated that HIF-1α triggers myocardial 
gluconeogenesis in response to ischemia. Specifically, we observed gluconeogenetic 
intermediates [m+3] isotopologues such as glucose-6-phosphate, fructose-6-phosphate, 
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and fructose 1,6-bisphosphate were only present in the HIF-1α ischemic hearts. The 
only theoretical source of the [m+3] molecules is from catabolism of the U-13C6 glucose 
(all six carbons are 13C-labeled) and the derived metabolites combining with 
endogenous unlabeled glucose-derived metabolites (Consult Figure. 2.3).   
Taken together, our data indicates that HIF-1α triggers active myocardial 
gluconeogenesis to enhance glucose:glycogen turnover and subsequent ATP 
production in response to ischemic stress. We surmise that the glycolytic ATP 
production provides energy in a compartmentalized fashion for ionic sarcolemmal 
function (i.e. Na+-K+ pump), thus promoting cellular ionic homeostasis. Without 
maintaining cellular ionic homeostasis, the cell membrane integrity would quickly 
degrade and the cell would die.  Therefore, these studies identify a novel 
cardioprotective mechanism for cardiomyocytes exposed to prolonged ischemic stress.  
These results also suggest that the steps of gluconeogenesis that is induced by 
HIF-1α, is the point where pyruvate is converted to OAA via pyruvate carboxylase (PC) 
for anaplerotic carboxylation rather than at the pyruvate dehydrogenase (PDH) reaction. 
This warrants further investigation.  
We have previously described several metabolic pathways upregulated by HIF-
1α possibly contribute to the energetic supply for gluconeogenesis in this model. For 
example, HIF-1α induces fumarate respiration allowing the cardiomyocyte to use 
fumarate as a terminal electron acceptor instead of O2 to sustain anaerobic 
mitochondrial polarization. In another alternative pathway leading to the synthesis of 
major metabolic end product succinate under anaerobic conditions, GTP is produced 
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from the conversion of α-ketoglutarate to succinate via substrate level phosphorylation 
(Hochachka et al. 1975). Our data show higher GTP levels in HIF-1α hearts at 30 min of 
ischemia, compared to WT.  
Future Studies with HIF-1α 
Taken together, we show that HIF-1α-induced gluconeogenesis in myocardia 
could contribute to the ischemic cardioprotection. Work on the very large metabolomics 
dataset will continued. Specific gluconeogenesis inhibitors exist. Future studies will 
utilize these these inhibitors to establish that the maintenance of glycolysis and 
glycogen reserves in HIF-1α hearts is dependent upon glyconeogenesis.  Loss of 
ischemic tolerance of the HIF-1α heart upon the blockade of gluconeogenesis would 
establish the cardioprotective role of this pathway.  In addition, the use of 13C labeled 
glucogenic amino acids will be employed to probe the carbon backbone source of the 
synthesized glucose in the HIF-1α hearts. 
CTRP3 
Although, we initially proposed that CTRP3 would also be cardioprotective, our 
studies indicate that  CTRP3 overexpression does not promote cardiofunctional 
recovery and tissue viability in ischemic mouse heart. These data suggest that CTRP3 
does not confer specific protective effect in myocardia, at least in this ex vivo model of 
hypoxic injury. However, CTRP3 transgenic mice failed to develop high fat diet-induced 
hepatic steatosis (Peterson et al. 2013). To pursue this further we investigated the 
CTRP3 specific effects in the lipid-overloaded hepatocyte.  
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As a polypeptide adipokine, after being released from adipocytes into blood, 
CTRP3 must reach the liver and bind to a receptor in hepatocytes to exert its regulative 
effects on hepatic lipid metabolism and inflammation. Our first set of experiments led to 
the successful identification of putative CTRP3 receptors, LAMP-1 and LIMP II, which 
may mediate hepatic metabolism. Further, we  demonstrated that  in the presence of 
excess fatty acids CTRP3 significantly enhance fatty acid utilization by hepatocytes. 
Thus, here CTRP3-induced fatty acids oxidation protects H4IIE hepatocytes against 
potential metabolic stress from lipid accumulation.  
Future Studies with CTRP3 
The specific function of LAMP1 is unknown and LAMP1 knockout animals do 
not present with an observable phenotype when fed standard chow diet (Andrejewski et 
al. 1999). Experiments with high-fat feeding with LAMP1 knockout animals have not 
been performed, and we propose that the loss of LAMP1 will ameliorate the hepato- 
protective effect of CTRP3. Further, as LAMP1 is not exclusive to hepatocytes (LAMP1 
is also found on macrophages) CTRP3 may act through blocking lipid-induced 
inflammation on the macrophages and hepatocytes. Therefore, future studies should be 
performed to identify whether CTRP3 binds directly to macrophages as well.  Lastly, as 
there is no known intracellular signaling pathway initiated by LAMP1 it could be that the 
binding of CTRP3 to LAMP1 is essential for inhibiting the binding of ligand to a separate 
receptor.  In support of this CTRP3 has been shown to block lipopolysaccharides (LPS) 
from activating the Toll-like receptor 4 in isolated macrophages, even though CTRP3 
did not bind directly to either the Toll-like receptor 4 or LPS (Kopp et al. 2010). Future 
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studies should be performed with macrophages and hepatocytes from LAMP1 knockout 
animals to test this potential mechanism.   
Conclusion 
Both HIF-1α and CTRP3 regulate metabolism and offer tissue specific 
protection to various stressors. 
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